Back to the tool

Data audit

CompanyYear US$ millionChange on the year before, % GradeReportedSourceWhereNote
Abbott2000 7300 – C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2001 7900 8.2 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2002 8500 7.6 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2003 9300 9.4 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2004 10000 7.5 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2005 10800 8.0 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2006 11600 7.4 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2007 12800 10.3 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2008 14300 11.7 C phx_est Segment note
Pharmaceutical Products segment (est.)Pharmaceutical Products segment (est.)
Pharm Exec 2009 15.6 bn; its change column (-6.7%) would imply 16.7 bn for 2008, which does not fit the 10-K segment (about 14 bn)
Estimate from memory of the segment figure; the Pharm Exec derived 2008 value is not used because FX/perimeter makes it inconsistent with the segment
Abbott2009 15600 9.1 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
abbott 15.6 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Abbott2010 19100 22.4 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2011 22400 17.3 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
abbott $22.4 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Abbott2012 22900 2.2 C phx_est selected data / segment note
Pharmaceutical Products segment (incl. the business later s…Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)
Abbott 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Abbott2013 4974 -78.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 4,974" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Abbott2014 5101 2.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 5,101" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Abbott2015 3720 -27.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 3,720" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Abbott2016 3859 3.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 3,859" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Abbott2017 4287 11.1 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 4,287" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Abbott2018 4422 3.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott ... 4,422" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Abbott2019 4486 1.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Abbott Laboratories ... 4,486" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Abbott2020 4486 0.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Abbott2021 4692 4.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Abbott2022 4885 4.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Abbott2023 5039 3.2 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Abbott2024 5166 2.5 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Abbott2025 5508 6.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
AbbVie2013 18790 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 18,790" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
AbbVie2014 19879 5.8 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 19,879" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
AbbVie2015 22724 14.3 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 22,724" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
AbbVie2016 25299 11.3 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 25,299" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
AbbVie2017 27743 9.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 27,743" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
AbbVie2018 32067 15.6 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 32,067" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
AbbVie2019 32351 0.9 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AbbVie ... 32,351" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
AbbVie2020 44341 37.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
AbbVie2021 55041 24.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
AbbVie2022 56179 2.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
AbbVie2023 52734 -6.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
AbbVie2024 54484 3.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
AbbVie2025 58271 7.0 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Actavis2013 7206 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Actavis ... 7,206" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Actavis2014 11130 54.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Actavis ... 11,130" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Actelion2016 2448 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Actelion ... 2,448" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Alexion2014 2234 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 2,234" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Alexion2015 2603 16.5 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 2,603" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Alexion2016 3082 18.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 3,082" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Alexion2017 3550 15.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 3,550" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Alexion2018 4130 16.3 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion ... 4,130" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Alexion2019 4990 20.8 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Alexion Pharmaceuticals ... 4,990" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Alexion2020 6069 21.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Alexion2021 3804 -37.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Allergan2002 1425 – C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exclu…Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Allergan2003 1771 24.3 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exclu…Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Allergan2004 2045 15.5 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exclu…Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Allergan2005 2319 13.4 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exclu…Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Allergan2006 2600 12.1 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exclu…Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Allergan2007 3200 23.1 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exclu…Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Allergan2008 3510 9.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
3700 / (1+5.3%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Allergan2009 3700 5.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
allergan 3.7 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Allergan2010 4000 8.1 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exclu…Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Allergan2011 4400 10.0 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
allergan $4.4 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Allergan2012 5000 13.6 C phx_est selected data / segment note
Net sales, specialty pharmaceuticals (medical devices exclu…Net sales, specialty pharmaceuticals (medical devices excluded from 2006)
Allergan net sales, approximated; device share removed from 2006
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Allergan2013 5398 8.0 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 5,398" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Allergan2014 6234 15.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 6,234" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Allergan2015 18403 195.2 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 18,403" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Allergan2016 18597 1.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 18,597" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Allergan2017 14906 -19.8 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 14,906" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Allergan2018 14700 -1.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 14,700" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Allergan2019 15153 3.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Allergan ... 15,153" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Allergan2020 4774 -68.5 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Amgen2000 3629 – B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2001 4016 10.7 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2002 5523 37.5 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2003 8356 51.3 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2004 10550 26.3 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2005 12430 17.8 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2006 14268 14.8 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2007 14771 3.5 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2008 14750 -0.1 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
14400 / (1-2.4%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Amgen2009 14400 -2.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
amgen 14.4 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Amgen2010 15053 4.5 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2011 15300 1.6 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
amgen $15.3 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Amgen2012 17265 12.8 B phx_est selected data / segment note
Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)
Amgen total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Amgen2013 18192 5.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 18,192" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Amgen2014 19327 6.2 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 19,327" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Amgen2015 20944 8.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 20,944" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Amgen2016 21892 4.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 21,892" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Amgen2017 21795 -0.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 21,795" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Amgen2018 22533 3.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 22,533" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Amgen2019 22204 -1.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Amgen ... 22,204" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Amgen2020 24098 8.5 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Amgen2021 23957 -0.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Amgen2022 22536 -5.9 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Amgen2023 26621 18.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Amgen2024 31748 19.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Amgen2025 34950 10.1 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
argenx2025 4151 – B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Aspen Pharmacare2013 2710 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 2,710" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Aspen Pharmacare2014 3066 13.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 3,066" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Aspen Pharmacare2015 2586 -15.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 2,586" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Aspen Pharmacare2016 2403 -7.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 2,403" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Aspen Pharmacare2017 2591 7.8 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aspen ... 2,591" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Astellas2005 7777 – B 879,361 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 879,361
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Astellas2006 7873 1.2 B 920,624 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 920,624
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Astellas2007 8543 8.5 B 972,586 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 972,586
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Astellas2008 9650 13.0 B 965,698 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 965,698
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Astellas2009 10511 8.9 B 974,877 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 974,877
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Astellas2010 11161 6.2 B 953,947 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 953,947
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Astellas2011 12285 10.1 B 969,387 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)
consolidated net sales 969,387
Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Astellas2012 10431 -15.1 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 10,431" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Astellas2014 10419 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 10,419" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Astellas2015 10937 5.0 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 10,937" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Astellas2016 11109 1.6 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 11,109" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Astellas2017 10888 -2.0 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 10,888" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Astellas2018 11036 1.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas ... 11,036" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Astellas2019 11444 3.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Astellas Pharma ... 11,444" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Astellas2020 11515 0.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Astellas2021 11828 2.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Astellas2022 10511 -11.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Astellas2023 10377 -1.3 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Astellas2024 11816 13.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Astellas2025 12597 6.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
AstraZeneca2000 15500 – C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2001 16480 6.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 16480 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2002 17841 8.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17841 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2003 18849 5.6 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18849 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2004 21426 13.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 21426 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2005 23950 11.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 23950 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2006 26475 10.5 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 26475 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2007 29559 11.6 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 29559 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2008 31601 6.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 31601 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2009 32804 3.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 32804 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2010 33269 1.4 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33269 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2011 33591 1.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33591 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2012 27973 -16.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total sales (pure-play pharma)Total sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27973 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
AstraZeneca2013 24523 -12.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 24,523" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
AstraZeneca2014 25694 4.8 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 25,694" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
AstraZeneca2015 23264 -9.5 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 23,264" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
AstraZeneca2016 20967 -9.9 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 20,967" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
AstraZeneca2017 19782 -5.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 19,782" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
AstraZeneca2018 20671 4.5 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 20,671" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
AstraZeneca2019 23207 12.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"AstraZeneca ... 23,207" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
AstraZeneca2020 25518 10.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
AstraZeneca2021 36131 41.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
AstraZeneca2022 42998 19.0 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
AstraZeneca2023 43790 1.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
AstraZeneca2024 50946 16.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
AstraZeneca2025 55038 8.0 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Aurobindo2019 2787 – B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Aurobindo Pharma ... 2,787" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Aurobindo2020 3000 7.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Aurobindo2021 3159 5.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Aventis2000 12281 – C 13,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vac…Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vaccines; Aventis CropScience and Behring excluded)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 13300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Aventis2001 12985 5.7 C 14,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vac…Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vaccines; Aventis CropScience and Behring excluded)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 14500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Aventis2002 15881 22.3 C 16,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vac…Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vaccines; Aventis CropScience and Behring excluded)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 16800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bausch Health2013 4196 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 4,196" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Bausch Health2014 5007 19.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 5,007" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Bausch Health2015 7013 40.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 7,013" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Bausch Health2016 6183 -11.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 6,183" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Bausch Health2017 5053 -18.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Valeant ... 5,053" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Bausch Health2018 4631 -8.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bausch Health ... 4,631" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Bausch Health2019 5295 14.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bausch Health Companies ... 5,295" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Bausch Health2020 4884 -7.8 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Bausch Health2021 4924 0.8 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Bausch Health2022 6569 33.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Bausch Health2023 4418 -32.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Bausch Health2024 4977 12.7 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Bausch Health2025 5406 8.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Baxalta2015 6148 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Baxalta ... 6,148" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Baxter2008 5320 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
5600 / (1+5.2%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Baxter2009 5600 5.3 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
baxter 5.6 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Baxter2011 6100 – B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
baxter $6.1 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Baxter2013 8265 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Baxter ... 8,265" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Baxter2014 8694 5.2 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Baxter ... 8,694" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Bayer2000 3601 – C 3,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2001 4119 14.4 C 4,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2002 4916 19.3 C 5,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2003 6338 28.9 C 5,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2004 7339 15.8 C 5,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2005 7841 6.8 C 6,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2006 11304 44.2 C 9,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2007 14532 28.6 C 10,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2008 14999 3.2 C 10,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2009 14490 -3.4 C 10,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2010 13674 -5.6 C 10,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2011 14477 5.9 C 10,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2012 14150 -2.3 C 11,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
HealthCare segment: Pharmaceuticals (Bayer Schering Pharma …HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Bayer2013 15594 10.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 15,594" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Bayer2014 16351 4.9 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 16,351" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Bayer2015 15558 -4.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 15,558" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Bayer2016 16886 8.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 16,886" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Bayer2017 17544 3.9 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 17,544" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Bayer2018 18221 3.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 18,221" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Bayer2019 18610 2.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bayer ... 18,610" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Bayer2020 18995 2.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Bayer2021 20119 5.9 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Bayer2022 18898 -6.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Bayer2023 17663 -6.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Bayer2024 17710 0.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Bayer2025 19188 8.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
BeiGene2024 3789 – B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Beijing Tong Ren Tang2000 124 – B 1,025 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 102,513.17" (10,000 CNY) = 1,025.13 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2001 195 57.3 B 1,612 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 161,250.39" (10,000 CNY) = 1,612.50 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2002 241 23.6 B 1,993 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 199,296.29" (10,000 CNY) = 1,992.96 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2003 263 9.1 B 2,174 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 217,364.96" (10,000 CNY) = 2,173.65 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2004 297 13.0 B 2,457 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 245,674.09" (10,000 CNY) = 2,456.74 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2005 319 7.5 B 2,614 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 261,355.38" (10,000 CNY) = 2,613.55 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2006 302 -5.3 B 2,408 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"主营业务收入 240,781.26" (10,000 CNY) = 2,407.81 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2007 355 17.7 B 2,703 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 270,285.09" (10,000 CNY) = 2,702.85 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2008 423 19.0 B 2,939 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 293,904.95" (10,000 CNY) = 2,939.05 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2009 476 12.4 B 3,250 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 325,021.99" (10,000 CNY) = 3,250.22 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2010 565 18.8 B 3,824 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 382,444.61" (10,000 CNY) = 3,824.45 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2011 945 67.3 B 6,108 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 610,838.37" (10,000 CNY) = 6,108.38 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2012 1190 25.8 B 7,504 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 750,403.20" (10,000 CNY) = 7,504.03 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2013 1418 19.2 B 8,715 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 871,464.74" (10,000 CNY) = 8,714.65 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2014 1572 10.9 B 9,686 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 968,586.75" (10,000 CNY) = 9,685.87 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2015 1721 9.4 B 10,809 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 1,080,876.12" (10,000 CNY) = 10,808.76 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2016 1821 5.8 B 12,091 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 1,209,074.01" (10,000 CNY) = 12,090.74 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2017 1980 8.7 B 13,376 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入/营业收入 1,337,596.63" (10,000 CNY) = 13,375.97 m
Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets.
Beijing Tong Ren Tang2018 2152 8.7 B 14,209 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 142.09亿元" = 14209 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Beijing Tong Ren Tang2019 1923 -10.6 B 13,277 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 132.77亿元" = 13277 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Beijing Tong Ren Tang2020 1860 -3.3 B 12,826 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 128.26亿元" = 12826 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Beijing Tong Ren Tang2021 2264 21.7 B 14,603 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 146.03亿元" = 14603 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Beijing Tong Ren Tang2022 2288 1.1 B 15,372 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 153.72亿元" = 15372 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Beijing Tong Ren Tang2023 2525 10.3 B 17,861 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 178.61亿元" = 17861 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Beijing Tong Ren Tang2024 2585 2.4 B 18,597 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 185.97亿元" = 18597 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Beijing Tong Ren Tang2025 2401 -7.1 B 17,256 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Beijing Tong Ren Tang C…Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)
"营业总收入 172.56亿元" = 17256 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
BeOne Medicines2025 5282 – B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Biogen2008 2840 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
3200 / (1+12.6%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Biogen2009 3200 12.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
biogen 3.2 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Biogen2011 3800 – B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
biogen $3.8 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Biogen2013 5429 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 5,429" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Biogen2014 8203 51.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 8,203" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Biogen2015 9189 12.0 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 9,189" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Biogen2016 9818 6.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 9,818" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Biogen2017 10355 5.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 10,355" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Biogen2018 10887 5.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 10,887" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Biogen2019 11380 4.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Biogen ... 11,380" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Biogen2020 10692 -6.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Biogen2021 8847 -17.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Biogen2022 7988 -9.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Biogen2023 7247 -9.3 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Biogen2024 7215 -0.4 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Biogen2025 7119 -1.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
BioNTech2022 3339 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Boehringer Ingelheim2000 3509 – C 3,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2001 3851 9.7 C 4,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2002 5010 30.1 C 5,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2003 6564 31.0 C 5,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2004 8210 25.1 C 6,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2005 9335 13.7 C 7,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2006 10425 11.7 C 8,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 8300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2007 12749 22.3 C 9,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2008 15146 18.8 C 10,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2009 14351 -5.2 C 10,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2010 14205 -1.0 C 10,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2011 15452 8.8 C 11,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2012 15050 -2.6 C 11,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net sales
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Boehringer Ingelheim2013 14468 -3.9 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 14,468" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Boehringer Ingelheim2014 13903 -3.9 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 13,903" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Boehringer Ingelheim2015 12348 -11.2 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 12,348" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Boehringer Ingelheim2016 13316 7.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 13,316" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Boehringer Ingelheim2017 14262 7.1 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 14,262" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Boehringer Ingelheim2018 14834 4.0 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer Ingelheim ... 14,834" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Boehringer Ingelheim2019 15629 5.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Boehringer-Ingelheim ... 15,629" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Boehringer Ingelheim2020 16456 5.3 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Boehringer Ingelheim2021 17806 8.2 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Boehringer Ingelheim2022 19473 9.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Boehringer Ingelheim2023 20613 5.9 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Boehringer Ingelheim2024 22175 7.6 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Boehringer Ingelheim2025 23817 7.4 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Bristol Myers Squibb2000 13000 – C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2001 14000 7.7 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2002 14200 1.4 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2003 15200 7.0 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2004 14600 -3.9 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2005 14500 -0.7 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2006 14900 2.8 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2007 15900 6.7 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2008 17690 11.3 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
18800 / (1+6.3%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Bristol Myers Squibb2009 18800 6.3 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
bms 18.8 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Bristol Myers Squibb2010 19500 3.7 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2011 21200 8.7 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
bms $21.2 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Bristol Myers Squibb2012 17600 -17.0 C phx_est selected data / segment note
Pharmaceuticals segment (excl. nutritionals, medical imagin…Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)
BMS segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Bristol Myers Squibb2013 12306 -30.1 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 12,306" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Bristol Myers Squibb2014 11969 -2.7 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 11,969" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Bristol Myers Squibb2015 14480 21.0 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 14,480" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Bristol Myers Squibb2016 18163 25.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 18,163" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Bristol Myers Squibb2017 19258 6.0 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 19,258" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Bristol Myers Squibb2018 21581 12.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 11
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 21,581" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Bristol Myers Squibb2019 40689 88.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Bristol-Myers Squibb ... 40,689" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Bristol Myers Squibb2020 41903 3.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Bristol Myers Squibb2021 45669 9.0 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Bristol Myers Squibb2022 45417 -0.6 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Bristol Myers Squibb2023 44398 -2.2 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Bristol Myers Squibb2024 47821 7.7 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Bristol Myers Squibb2025 47748 -0.2 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Celgene2003 271 – B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Celgene2004 377 39.1 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Celgene2005 537 42.4 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Celgene2006 899 67.4 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Celgene2007 1406 56.4 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Celgene2008 2160 53.6 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
2600 / (1+20.1%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Celgene2009 2600 20.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
celgene 2.6 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Celgene2010 3626 39.5 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Celgene2011 4700 29.6 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
celgene $4.7 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Celgene2012 5506 17.1 B phx_est selected data / segment note
Total revenueTotal revenue
Celgene total revenue
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Celgene2013 6359 15.5 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 6,359" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Celgene2014 7476 17.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 7,476" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Celgene2015 9069 21.3 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 9,069" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Celgene2016 11114 22.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 11,114" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Celgene2017 12928 16.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 12,928" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Celgene2018 15238 17.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Celgene ... 15,238" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
China Resources Double-Crane2000 142 – B 1,175 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 117,533.59" (10,000 CNY) = 1,175.34 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2001 289 103.7 B 2,394 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 239,376.91" (10,000 CNY) = 2,393.77 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2002 448 55.0 B 3,710 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 371,008.74" (10,000 CNY) = 3,710.09 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2003 517 15.4 B 4,280 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 428,000.98" (10,000 CNY) = 4,280.01 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2004 509 -1.6 B 4,210 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 420,974.07" (10,000 CNY) = 4,209.74 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2005 563 10.6 B 4,611 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 461,061.95" (10,000 CNY) = 4,610.62 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2006 510 -9.3 B 4,067 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"主营业务收入 406,673.72" (10,000 CNY) = 4,066.74 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2007 599 17.5 B 4,557 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 455,661.64" (10,000 CNY) = 4,556.62 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2008 713 19.0 B 4,952 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 495,152.44" (10,000 CNY) = 4,951.52 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2009 738 3.5 B 5,038 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 503,794.64" (10,000 CNY) = 5,037.95 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2010 793 7.5 B 5,367 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 536,679.58" (10,000 CNY) = 5,366.80 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2011 988 24.6 B 6,383 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 638,337.53" (10,000 CNY) = 6,383.38 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2012 1108 12.2 B 6,989 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 698,932.34" (10,000 CNY) = 6,989.32 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2013 1112 0.3 B 6,835 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 683,457.43" (10,000 CNY) = 6,834.57 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2014 695 -37.5 B 4,281 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 428,096.10" (10,000 CNY) = 4,280.96 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2015 818 17.7 B 5,138 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 513,839.54" (10,000 CNY) = 5,138.40 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2016 828 1.2 B 5,495 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 549,480.39" (10,000 CNY) = 5,494.80 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2017 951 14.9 B 6,422 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入/营业收入 642,184.68" (10,000 CNY) = 6,421.85 m
Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported.
China Resources Double-Crane2018 1246 31.0 B 8,225 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 82.25亿元" = 8225 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Double-Crane2019 1359 9.1 B 9,381 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 93.81亿元" = 9381 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Double-Crane2020 1233 -9.2 B 8,504 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 85.04亿元" = 8504 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Double-Crane2021 1413 14.5 B 9,112 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 91.12亿元" = 9112 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Double-Crane2022 1433 1.4 B 9,625 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 96.25亿元" = 9625 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Double-Crane2023 1599 11.6 B 11,310 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 113.10亿元" = 11310 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Double-Crane2024 1558 -2.5 B 11,212 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 112.12亿元" = 11212 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Double-Crane2025 1531 -1.8 B 11,001 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Double-…Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)
"营业总收入 110.01亿元" = 11001 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Sanjiu2000 198 – B 1,635 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 163,500.67" (10,000 CNY) = 1,635.01 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2001 226 14.5 B 1,871 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 187,120.28" (10,000 CNY) = 1,871.20 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2002 263 16.1 B 2,173 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 217,318.87" (10,000 CNY) = 2,173.19 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2003 324 23.6 B 2,686 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 268,592.01" (10,000 CNY) = 2,685.92 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2004 300 -7.6 B 2,482 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 248,160.36" (10,000 CNY) = 2,481.60 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2005 366 22.0 B 2,997 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 299,669.16" (10,000 CNY) = 2,996.69 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2006 364 -0.4 B 2,904 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"主营业务收入 290,423.25" (10,000 CNY) = 2,904.23 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2007 457 25.5 B 3,478 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 347,756.12" (10,000 CNY) = 3,477.56 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2008 621 35.9 B 4,316 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 431,618.69" (10,000 CNY) = 4,316.19 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2009 710 14.3 B 4,853 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 485,271.70" (10,000 CNY) = 4,852.72 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2010 645 -9.2 B 4,365 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 436,515.33" (10,000 CNY) = 4,365.15 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2011 855 32.6 B 5,525 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 552,522.29" (10,000 CNY) = 5,525.22 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2012 1092 27.8 B 6,891 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 689,110.26" (10,000 CNY) = 6,891.10 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2013 1269 16.2 B 7,802 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 780,160.37" (10,000 CNY) = 7,801.60 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2014 1181 -6.9 B 7,277 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 727,658.56" (10,000 CNY) = 7,276.59 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2015 1258 6.5 B 7,900 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 790,018.96" (10,000 CNY) = 7,900.19 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2016 1353 7.6 B 8,982 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 898,172.11" (10,000 CNY) = 8,981.72 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2017 1646 21.7 B 11,120 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入/营业收入 1,111,991.64" (10,000 CNY) = 11,119.92 m
Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous.
China Resources Sanjiu2018 2034 23.5 B 13,428 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 134.28亿元" = 13428 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Sanjiu2019 2143 5.4 B 14,794 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 147.94亿元" = 14794 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Sanjiu2020 1978 -7.7 B 13,637 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 136.37亿元" = 13637 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Sanjiu2021 2410 21.9 B 15,544 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 155.44亿元" = 15544 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Sanjiu2022 2691 11.7 B 18,079 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 180.79亿元" = 18079 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Sanjiu2023 3497 29.9 B 24,739 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 247.39亿元" = 24739 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Sanjiu2024 3838 9.8 B 27,617 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 276.17亿元" = 27617 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
China Resources Sanjiu2025 4397 14.6 B 31,603 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company China Resources Sanjiu …Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)
"营业总收入 316.03亿元" = 31603 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Chugai2001 1695 – B 211,700 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 211,700
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2003 2010 – B 232,700 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 232,700
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2004 2726 35.6 B 294,670 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 294,670
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2005 2976 9.2 B 327,155 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 327,155
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2006 2803 -5.8 B 326,109 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 326,109
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2007 2931 4.5 B 344,808 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 344,808
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2008 3171 8.2 B 326,937 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 326,937
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2009 4588 44.7 B 428,947 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 428,947
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). 2009 includes the Tamiflu stockpiling boom. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2010 4334 -5.6 B 379,509 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 379,509
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2011 4690 8.2 B 373,516 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 373,516
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2012 4905 4.6 B 391,220 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)
consolidated net sales 391,220
Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Chugai2013 3648 -25.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,648" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Chugai2014 3576 -2.0 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,576" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Chugai2015 3297 -7.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,297" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Chugai2016 3699 12.2 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,699" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Chugai2017 3688 -0.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,688" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Chugai2018 3649 -1.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai ... 3,649" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Chugai2019 3996 9.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Chugai Pharmaceutical ... 3,996" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Chugai2020 3881 -2.9 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Chugai2022 1120 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Chugai2023 4036 260.4 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
CJ CheilJedang2015 3228 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CJ CheilJedang ... 3,228" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
CSL2000 582 – C 1,000 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2001 620 6.7 C 1,200 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1200 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2002 761 22.7 C 1,400 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1400 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2003 1109 45.7 C 1,700 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2004 1326 19.6 C 1,800 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2005 1525 15.0 C 2,000 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2000 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2006 1658 8.7 C 2,200 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2200 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2007 2097 26.5 C 2,500 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2500 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2008 2642 26.0 C 3,100 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2009 3248 22.9 C 4,100 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2010 4050 24.7 C 4,400 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4400 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2011 4751 17.3 C 4,600 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4600 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2012 5181 9.0 C 5,000 AUD m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5000 AUD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
CSL2013 4875 -5.9 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 4,875" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
CSL2014 4743 -2.7 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 4,743" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
CSL2015 6294 32.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 6,294" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
CSL2016 6674 6.0 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 6,674" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
CSL2017 7522 12.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 7,522" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
CSL2018 8270 9.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 8,270" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
CSL2019 8951 8.2 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"CSL ... 8,951" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
CSL2020 9656 7.9 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
CSL2021 10444 8.2 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
CSL2022 13123 25.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
CSL2023 14176 8.0 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
CSL2024 15009 5.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
CSL2025 15441 2.9 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
CSPC Pharmaceutical2009 774 – C 6,000 HKD m phx_cn_cspc+phx_cn_est+fx_fed_h10 Financial Summary (p.120)
Estimated revenue of the full CSPC pharmaceutical group (HK…Estimated revenue of the full CSPC pharmaceutical group (HK$)
Listed vehicle revenue HK$ 1,296.3 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year
The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C.
CSPC Pharmaceutical2010 850 9.8 C 6,600 HKD m phx_cn_cspc+phx_cn_est+fx_fed_h10 Financial Summary (p.120)
Estimated revenue of the full CSPC pharmaceutical group (HK…Estimated revenue of the full CSPC pharmaceutical group (HK$)
Listed vehicle revenue HK$ 1,757.6 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year
The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C.
CSPC Pharmaceutical2011 964 13.4 C 7,500 HKD m phx_cn_cspc+phx_cn_est+fx_fed_h10 Financial Summary (p.120)
Estimated revenue of the full CSPC pharmaceutical group (HK…Estimated revenue of the full CSPC pharmaceutical group (HK$)
Listed vehicle revenue HK$ 2,407.4 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year
The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C.
CSPC Pharmaceutical2012 1109 15.1 C 8,600 HKD m phx_cn_cspc+phx_cn_est+fx_fed_h10 Financial Summary (p.120)
Estimated revenue of the full CSPC pharmaceutical group (HK…Estimated revenue of the full CSPC pharmaceutical group (HK$)
Listed vehicle revenue HK$ 4,146.4 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year
The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C.
CSPC Pharmaceutical2013 1283 15.7 B 9,949 HKD m phx_cn_cspc+fx_fed_h10 Financial Summary
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
Revenue 9,949,103 (HK$'000)
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
CSPC Pharmaceutical2014 1413 10.1 B 10,955 HKD m phx_cn_cspc+fx_fed_h10 Financial Summary
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
Revenue 10,955,077 (HK$'000)
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
CSPC Pharmaceutical2015 1470 4.0 B 11,394 HKD m phx_cn_cspc+fx_fed_h10 consolidated statement of profit or loss, 2015 comparative (via search summary)
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
Revenue HK$11,393.7 m
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
CSPC Pharmaceutical2016 1593 8.4 B 12,369 HKD m phx_cn_cspc+fx_fed_h10 consolidated statement of profit or loss (via search summary)
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
Revenue HK$12,369.0 m
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
CSPC Pharmaceutical2017 1984 24.5 B 15,463 HKD m phx_cn_cspc+fx_fed_h10 turnover chart in the 2018 report (via search summary)
Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)
about HK$15,463 m
HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified.
CSPC Pharmaceutical2018 2683 35.2 B 21,029 HKD m phx_cn_cspc_res+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
"revenue HK$21,029 million, +36.0%"
HK$ as originally reported (restated to RMB 17,716.5 m in the 2019 report)
CSPC Pharmaceutical2019 3201 19.3 B 22,103 CNY m phx_cn_cspc_res+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
"Revenue RMB22,103 million, +24.8%"
Reporting currency changed to RMB from 2019
CSPC Pharmaceutical2020 3617 13.0 B 24,942 CNY m phx_cn_cspc_res+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
"revenue +12.8% to RMB24,942 million"
Annual results
CSPC Pharmaceutical2021 4321 19.4 B 27,867 CNY m phx_cn_cspc_res+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
"+11.7% to RMB27,867 million"
Matches company filing quoted in search
CSPC Pharmaceutical2022 4606 6.6 B 30,937 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
Revenue FY2022 30,937
Third-party table (S&P Global data)
CSPC Pharmaceutical2023 4445 -3.5 B 31,450 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
Revenue FY2023 31,450
Third-party table (S&P Global data)
CSPC Pharmaceutical2024 4032 -9.3 B 29,009 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
Revenue FY2024 29,009
Third-party table; another aggregator shows 27,758
CSPC Pharmaceutical2025 3619 -10.2 B 26,006 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)
Revenue FY2025 26,006
Third-party table; audited FY2025 results published March 2026
Daiichi Pharmaceutical2002 2643 – A 321,926 JPY m phx_daiichi_20f+fx_fed_h10 Form 20-F FY2005, consolidated statements of income
Consolidated net sales (pure-play pharma)Consolidated net sales (pure-play pharma)
net sales 321,926 (yen m)
Read from the income statement; the Selected Financial Data section (FY2001-02) not reached.
Daiichi Pharmaceutical2003 2865 8.4 A 322,977 JPY m phx_daiichi_20f+fx_fed_h10 Form 20-F FY2005, consolidated statements of income
Consolidated net sales (pure-play pharma)Consolidated net sales (pure-play pharma)
net sales 322,977 (yen m)
Read from the income statement; the Selected Financial Data section (FY2001-02) not reached.
Daiichi Pharmaceutical2004 3024 5.6 A 324,860 JPY m phx_daiichi_20f+fx_fed_h10 Form 20-F FY2005, consolidated statements of income
Consolidated net sales (pure-play pharma)Consolidated net sales (pure-play pharma)
net sales 324,860 (yen m)
Read from the income statement; the Selected Financial Data section (FY2001-02) not reached.
Daiichi Sankyo2005 8189 – B 925,918 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 925,918
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Daiichi Sankyo2006 7949 -2.9 B 929,506 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 929,506
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Daiichi Sankyo2007 7731 -2.7 B 880,120 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 880,120
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Daiichi Sankyo2008 8415 8.9 B 842,147 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 842,147
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Daiichi Sankyo2009 10265 22.0 B 952,105 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 952,105
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Daiichi Sankyo2010 11318 10.3 B 967,365 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 967,365
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Daiichi Sankyo2011 11896 5.1 B 938,677 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
consolidated net sales 938,677
FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Daiichi Sankyo2012 10268 -13.7 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 10,268" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Daiichi Sankyo2014 7575 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,575" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Daiichi Sankyo2015 7215 -4.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,215" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Daiichi Sankyo2016 7535 4.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,535" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Daiichi Sankyo2017 7358 -2.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,358" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Daiichi Sankyo2018 7033 -4.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,033" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Daiichi Sankyo2019 7942 12.9 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Daiichi Sankyo ... 7,942" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Daiichi Sankyo2020 8029 1.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Daiichi Sankyo2021 7261 -9.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Daiichi Sankyo2022 7089 -2.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Daiichi Sankyo2023 8091 14.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Daiichi Sankyo2024 10912 34.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Daiichi Sankyo2025 12039 10.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Dainippon Pharmaceutical2000 1223 – C 135,065 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 158,900 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Dainippon Pharmaceutical2001 1117 -8.7 C 139,499 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 164,117 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Dainippon Pharmaceutical2002 1202 7.6 C 146,337 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 172,161 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Dainippon Pharmaceutical2003 1288 7.2 C 145,216 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 170,842 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Dainippon Pharmaceutical2004 1376 6.8 C 147,814 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.85
group net sales 173,899 x 0.85
Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Dong-E E-Jiao2000 49 – B 406 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 40,637.05" (10,000 CNY) = 406.37 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2001 55 11.4 B 453 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 45,266.70" (10,000 CNY) = 452.67 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2002 69 26.1 B 571 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 57,059.66" (10,000 CNY) = 570.60 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2003 90 31.2 B 748 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 74,839.77" (10,000 CNY) = 748.40 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2004 107 18.0 B 883 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 88,295.38" (10,000 CNY) = 882.95 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2005 115 7.6 B 941 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 94,053.82" (10,000 CNY) = 940.54 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2006 135 17.2 B 1,073 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"主营业务收入 107,291.00" (10,000 CNY) = 1,072.91 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2007 182 35.0 B 1,381 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 138,136.07" (10,000 CNY) = 1,381.36 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2008 243 33.6 B 1,686 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 168,595.53" (10,000 CNY) = 1,685.96 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2009 304 25.4 B 2,079 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 207,910.61" (10,000 CNY) = 2,079.11 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2010 364 19.6 B 2,464 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 246,378.43" (10,000 CNY) = 2,463.78 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2011 427 17.3 B 2,759 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 275,884.83" (10,000 CNY) = 2,758.85 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2012 484 13.5 B 3,056 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 305,607.43" (10,000 CNY) = 3,056.07 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2013 653 34.9 B 4,016 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 401,630.44" (10,000 CNY) = 4,016.30 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2014 651 -0.4 B 4,009 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 400,901.05" (10,000 CNY) = 4,009.01 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2015 868 33.3 B 5,450 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 544,966.32" (10,000 CNY) = 5,449.66 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2016 951 9.7 B 6,317 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 631,713.53" (10,000 CNY) = 6,317.14 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2017 1092 14.7 B 7,372 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入/营业收入 737,234.03" (10,000 CNY) = 7,372.34 m
Sina Finance table for stock 000423.
Dong-E E-Jiao2018 1111 1.8 B 7,338 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 73.38亿元" = 7338 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Dong-E E-Jiao2019 430 -61.3 B 2,970 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 29.70亿元" = 2970 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table; 2019 drop reflects the sharp fall in sales (channel destocking)
Dong-E E-Jiao2020 494 14.9 B 3,409 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 34.09亿元" = 3409 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Dong-E E-Jiao2021 597 20.7 B 3,849 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 38.49亿元" = 3849 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Dong-E E-Jiao2022 602 0.8 B 4,042 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 40.42亿元" = 4042 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Dong-E E-Jiao2023 666 10.7 B 4,715 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 47.15亿元" = 4715 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Dong-E E-Jiao2024 856 28.4 B 6,157 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 61.57亿元" = 6157 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Dong-E E-Jiao2025 932 8.9 B 6,700 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Shandong Dong-E E-Jiao …Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)
"营业总收入 67.00亿元" = 6700 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Dr. Reddy’s2007 1247 – B 50,006 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 50,006 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
Dr. Reddy’s2008 1522 22.0 B 69,441 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 69,441 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
Dr. Reddy’s2009 1485 -2.4 B 70,277 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 70,277 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
Dr. Reddy’s2010 1642 10.6 B 74,693 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 74,693 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
Dr. Reddy’s2011 2029 23.5 B 96,737 INR m phx_drl_20f+fx_fed_h10 Form 20-F FY2012, selected data (IFRS)
Total revenues (IFRS)Total revenues (IFRS)
revenues 96,737 (Rs m)
Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business.
Dr. Reddy’s2023 3007 – B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Dr. Reddy’s2024 3304 9.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Eisai2000 2719 – C 300,211 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 361,700 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2001 2868 5.5 C 358,289 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 431,673 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2002 3180 10.9 C 387,278 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 466,600 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2003 3682 15.8 C 415,083 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 500,100 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2004 4118 11.9 C 442,390 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 533,000 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2005 4414 7.2 C 499,039 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 601,252 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2006 4785 8.4 C 559,512 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 674,111 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2007 5353 11.9 C 609,457 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 734,286 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2008 6484 21.1 C 648,847 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 781,743 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2009 7187 10.8 C 666,616 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 803,152 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2010 7467 3.9 C 638,199 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 768,914 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2011 6816 -8.7 C 537,820 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83
group net sales 647,976 x 0.83
Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Eisai2012 4821 -29.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,821" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Eisai2014 4422 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,422" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Eisai2015 3909 -11.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 3,909" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Eisai2016 4301 10.0 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,301" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Eisai2017 4359 1.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,359" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Eisai2018 4531 3.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,531" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Eisai2019 4703 3.8 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eisai ... 4,703" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Eisai2020 5107 8.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Eisai2021 5224 2.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Eisai2022 4596 -12.0 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Eisai2023 4305 -6.3 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Eisai2024 4536 5.4 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Eisai2025 4775 5.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Eli Lilly2000 10862 – B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2001 11543 6.3 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2002 11078 -4.0 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2003 12583 13.6 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2004 13858 10.1 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2005 14645 5.7 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2006 15691 7.1 B phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2007 17200 9.6 C phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2008 19330 12.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
21200 / (1+9.7%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Eli Lilly2009 21200 9.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
lilly 21.2 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Eli Lilly2010 21700 2.4 C phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2011 21900 0.9 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
lilly $21.9 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Eli Lilly2012 20500 -6.4 C phx_est selected data / segment note
Net sales, pharmaceutical (Elanco animal health excluded fr…Net sales, pharmaceutical (Elanco animal health excluded from 2007)
Lilly net sales 2000-06 as reported; 2007+ total less Elanco
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Eli Lilly2013 20119 -1.9 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 20,119" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Eli Lilly2014 16349 -18.7 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 16,349" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Eli Lilly2015 15792 -3.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 15,792" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Eli Lilly2016 17173 8.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 17,173" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Eli Lilly2017 18532 7.9 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 18,532" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Eli Lilly2018 19580 5.7 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 19,580" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Eli Lilly2019 20085 2.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Eli Lilly ... 20,085" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Eli Lilly2020 22646 12.8 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Eli Lilly2021 25958 14.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Eli Lilly2022 25463 -1.9 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Eli Lilly2023 31868 25.2 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Eli Lilly2024 40716 27.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Eli Lilly2025 60777 49.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Endo2014 2238 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 2,238" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Endo2015 2856 27.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 2,856" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Endo2016 4010 40.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 4,010" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Endo2017 3469 -13.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 3,469" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Endo2018 2947 -15.0 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo ... 2,947" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Endo2019 2887 -2.0 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Endo International ... 2,887" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Endo2020 2897 0.3 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Endo2021 2990 3.2 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Ferring2016 2134 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ferring ... 2,134" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Ferring2017 2243 5.1 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ferring ... 2,243" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Ferring2018 2461 9.7 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ferring ... 2,461" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Forest Laboratories2008 3460 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
3600 / (1+3.9%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Forest Laboratories2009 3600 4.0 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
forest 3.6 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn; Forest fiscal year to March
Forest Laboratories2011 4200 – B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
forest $4.2 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn; Forest fiscal year to March
Forest Laboratories2013 3380 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Forest Laboratories ... 3,380" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2000 42 – C 346 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2000-12-31
Pharmaceutical manufacturing estimated as 60% of total reve…Pharmaceutical manufacturing estimated as 60% of total revenue
total 576.14 m x 60% = 345.68 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2001 53 27.0 C 439 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2001-12-31
Pharmaceutical manufacturing estimated as 60% of total reve…Pharmaceutical manufacturing estimated as 60% of total revenue
total 731.59 m x 60% = 438.95 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2002 76 42.6 C 626 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2002-12-31
Pharmaceutical manufacturing estimated as 60% of total reve…Pharmaceutical manufacturing estimated as 60% of total revenue
total 1,043.19 m x 60% = 625.92 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2003 158 108.9 C 1,307 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2003-12-31
Pharmaceutical manufacturing estimated as 60% of total reve…Pharmaceutical manufacturing estimated as 60% of total revenue
total 2,178.79 m x 60% = 1,307.27 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2004 179 13.1 C 1,478 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2004-12-31
Pharmaceutical manufacturing estimated as 60% of total reve…Pharmaceutical manufacturing estimated as 60% of total revenue
total 2,463.52 m x 60% = 1,478.11 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2005 223 25.1 C 1,830 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2005-12-31
Pharmaceutical manufacturing estimated as 60% of total reve…Pharmaceutical manufacturing estimated as 60% of total revenue
total 3,050.15 m x 60% = 1,830.09 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2006 239 6.8 C 1,901 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2006-12-31
Pharmaceutical manufacturing estimated as 60% of total reve…Pharmaceutical manufacturing estimated as 60% of total revenue
total 3,168.68 m x 60% = 1,901.21 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2007 291 22.2 C 2,216 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2007-12-31
Pharmaceutical manufacturing estimated as 60% of total reve…Pharmaceutical manufacturing estimated as 60% of total revenue
total 3,693.30 m x 60% = 2,215.98 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2008 326 11.8 C 2,264 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2008-12-31
Pharmaceutical manufacturing estimated as 60% of total reve…Pharmaceutical manufacturing estimated as 60% of total revenue
total 3,773.23 m x 60% = 2,263.94 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2009 333 2.2 B 2,275 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
2,812 / 1.2361 (2010 segment 2,812, +23.61%)
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2010 415 24.7 B 2,812 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
2010 pharmaceutical manufacturing segment revenue RMB 2.812 bn, +23.61%
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2011 622 49.8 C 4,021 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2011-12-31
Pharmaceutical manufacturing estimated as 62% of total reve…Pharmaceutical manufacturing estimated as 62% of total revenue
total 6,485.54 m x 62% = 4,021.04 m
Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2012 734 18.0 B 4,633 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
6,524 / 1.4082 (2013 segment 6,524, +40.82% on 2012)
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2013 1061 44.5 B 6,524 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
Pharmaceutical manufacturing and R&D segment revenue RMB 6,524 m, +40.82%
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2014 1191 12.2 B 7,338 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
R&D RMB 452 m = 6.16% of segment revenue -> 452/0.0616 = 7,338
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2015 1408 18.2 B 8,843 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
Segment revenue 8,843 (comparative in 2017 annual results)
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2016 1529 8.6 B 10,150 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
Segment revenue 10,150, +14.78%
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2017 1931 26.3 B 13,043 CNY m phx_cn_fosun+fx_fed_h10 Segment information (read via search summaries of Fosun results and releases, documents not opened)
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
Segment revenue 13,043 (2017 annual results; a Fosun release gives 13,195.47)
Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn.
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2018 2785 44.2 C 18,390 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (estim…Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 249.18亿 x 73.80% = 18389 RMB m
Share interpolated between the reported 2017/2019 and 2022/2023 shares (about 68-76%); segment table not retrieved
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2019 3157 13.3 B 21,796 CNY m phx_cn_10jqka+phx_cn_fosun_rep+fx_fed_h… annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (estim…Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 285.85亿 x 76.25% = 21796 RMB m
Broker note quotes pharma share 76.25% in 2019 (71.33% in 2017); segment table not retrieved
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2020 3341 5.8 C 23,033 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (estim…Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 303.07亿 x 76.00% = 23033 RMB m
Share interpolated between the reported 2017/2019 and 2022/2023 shares (about 68-76%); segment table not retrieved
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2021 4113 23.1 C 26,528 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (estim…Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 390.11亿 x 68.00% = 26527 RMB m
Share interpolated between the reported 2017/2019 and 2022/2023 shares (about 68-76%); segment table not retrieved
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2022 4587 11.5 B 30,810 CNY m phx_cn_fosun_rep+fx_fed_h10 article text
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
2023 pharma 302.22亿, -1.91% yoy => 2022 = 302.22/0.9809 = 30,811
Backed out from the reported 2023 figure and its growth rate
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2023 4272 -6.9 B 30,222 CNY m phx_cn_fosun_rep+fx_fed_h10 article text
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
"制药板块 302.22亿元, -1.91%"
Article reprint of the annual report
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2024 4109 -3.8 C 29,568 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing and R&D segment revenue (estim…Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)
group 410.67亿 x 72% = 29,568 RMB m
Share of about 72% bracketed by 73.0% (2023) and 71.6% (2025); segment table not retrieved
Fosun Pharma (pharmaceutical manufacturing and R&D segment)2025 4151 1.0 B 29,834 CNY m phx_cn_fosun_ann25+fx_fed_h10 results summary
Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue
innovative drug revenue RMB 9.893 bn = 33.16% of pharmaceutical business revenue => 29,834
Derived from two reported figures (innovative drugs and their share)
Fresenius2013 3604 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 3,604" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Fresenius2014 3707 2.9 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 3,707" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Fresenius2015 3709 0.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 3,709" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Fresenius2016 3753 1.2 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 3,753" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Fresenius2017 4070 8.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 4,070" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Fresenius2018 4328 6.3 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius ... 4,328" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Fresenius2019 4224 -2.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Fresenius Kabi ... 4,224" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Fresenius2020 4221 -0.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Fresenius2021 4224 0.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Fresenius2022 4342 2.8 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Fresenius2023 4538 4.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Fresenius2024 4810 6.0 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Fresenius2025 5206 8.2 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Genentech2004 4621 – B phx_est selected data / segment note
Total operating revenues (product sales + royalties + contr…Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Genentech2005 6633 43.5 B phx_est selected data / segment note
Total operating revenues (product sales + royalties + contr…Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Genentech2006 9284 40.0 B phx_est selected data / segment note
Total operating revenues (product sales + royalties + contr…Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Genentech2007 11724 26.3 B phx_est selected data / segment note
Total operating revenues (product sales + royalties + contr…Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Genentech2008 13418 14.4 B phx_est selected data / segment note
Total operating revenues (product sales + royalties + contr…Total operating revenues (product sales + royalties + contract)
Genentech total operating revenues; acquired by Roche Mar 2009
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Genzyme2008 4220 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
4100 / (1-2.9%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Genzyme2009 4100 -2.8 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
genzyme 4.1 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Genzyme2010 4000 -2.4 C phx_est selected data / segment note
Total revenues x ~0.9 (Pharm Exec basis)Total revenues x ~0.9 (Pharm Exec basis)
Genzyme revenue ~4.0-4.5 bn 2009-10; acquired by Sanofi Apr 2011
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Gilead Sciences2002 466 – C phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Gilead Sciences2004 1325 – B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Gilead Sciences2005 2028 53.1 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Gilead Sciences2006 3026 49.2 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Gilead Sciences2007 4230 39.8 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Gilead Sciences2008 5130 21.3 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
6500 / (1+26.8%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Gilead Sciences2009 6500 26.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
gilead 6.5 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Gilead Sciences2010 7949 22.3 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Gilead Sciences2011 8100 1.9 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
gilead $8.1 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Gilead Sciences2012 9702 19.8 B phx_est selected data / segment note
Total revenuesTotal revenues
Gilead total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Gilead Sciences2013 10804 11.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 10,804" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Gilead Sciences2014 24474 126.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 24,474" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Gilead Sciences2015 32151 31.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 32,151" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Gilead Sciences2016 29992 -6.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 29,992" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Gilead Sciences2017 25662 -14.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 25,662" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Gilead Sciences2018 21677 -15.5 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Sciences ... 21,677" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Gilead Sciences2019 21703 0.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Gilead Science ... 21,703" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Gilead Sciences2020 23806 9.7 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Gilead Sciences2021 27005 13.4 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Gilead Sciences2022 26615 -1.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Gilead Sciences2023 26461 -0.6 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Gilead Sciences2024 28028 5.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Gilead Sciences2025 28828 2.9 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Grifols2000 185 – C 200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2001 224 21.2 C 250 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 250 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2002 378 68.9 C 400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2003 566 49.6 C 500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2004 746 31.9 C 600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2005 871 16.7 C 700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2006 1005 15.3 C 800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2007 1234 22.8 C 900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2008 1470 19.2 C 1,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2009 1533 4.2 C 1,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2010 1726 12.6 C 1,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2011 3898 125.8 C 2,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2012 3988 2.3 C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net revenues (plasma-derived pharma, Diagnostic/Hospi…Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Grifols2013 3245 -18.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,245" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Grifols2014 3255 0.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,255" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Grifols2015 3365 3.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,365" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Grifols2016 3572 6.2 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,572" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Grifols2017 3876 8.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 3,876" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Grifols2018 4154 7.2 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 4,154" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Grifols2019 4471 7.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Grifols ... 4,471" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Grifols2021 4516 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Grifols2022 4864 7.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Grifols2023 6012 23.6 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Grifols2024 6646 10.5 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Grifols2025 7332 10.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
GSK2000 22889 – C 15,100 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15100 GBP m
2000 = group turnover ~18,079 less Consumer Healthcare ~3,000
GSK2001 24776 8.2 B 17,205 GBP m phx_gsk20f2005+fx_fed_h10 Financial record, Pharmaceuticals turnover (UK GAAP)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Pharmaceuticals turnover 17205 GBP m (as relayed by search summary of 20-F FY2005)
UK GAAP; 2003 IFRS equivalent about 18,114; read via search summary, not the table itself
GSK2002 27036 9.1 B 17,995 GBP m phx_gsk20f2005+fx_fed_h10 Financial record, Pharmaceuticals turnover (UK GAAP)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Pharmaceuticals turnover 17995 GBP m (as relayed by search summary of 20-F FY2005)
UK GAAP; 2003 IFRS equivalent about 18,114; read via search summary, not the table itself
GSK2003 29612 9.5 B 18,114 GBP m phx_gsk20f2005+fx_fed_h10 Financial record, Pharmaceuticals turnover (UK GAAP)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Pharmaceuticals turnover 18114 GBP m (as relayed by search summary of 20-F FY2005)
UK GAAP; 2003 IFRS equivalent about 18,114; read via search summary, not the table itself; IFRS-restated 2003 = 18,114
GSK2004 31337 5.8 C 17,100 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17100 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
GSK2005 33960 8.4 C 18,661 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18661 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
GSK2006 37412 10.2 C 20,300 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 20300 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
GSK2007 39433 5.4 C 19,700 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 19700 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
GSK2008 39637 0.5 C 21,400 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 21400 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
GSK2009 38191 -3.6 C 24,400 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24400 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
GSK2010 37890 -0.8 C 24,500 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24500 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
GSK2011 38007 0.3 C 23,700 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 23700 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
GSK2012 35199 -7.4 C 22,200 GBP m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals turnover incl. vaccines (excl. Consumer Hea…Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 22200 GBP m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
GSK2013 33055 -6.1 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 33,055" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
GSK2014 30302 -8.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 30,302" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
GSK2015 27051 -10.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 27,051" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
GSK2016 27775 2.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 27,775" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
GSK2017 28668 3.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 28,668" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
GSK2018 30645 6.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 8
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 30,645" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
GSK2019 31288 2.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 9
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"GlaxoSmithKline ... 31,288" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
GSK2020 30585 -2.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
GSK2021 33443 9.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
GSK2022 38254 14.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
GSK2023 36758 -3.9 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
GSK2024 39718 8.1 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
GSK2025 42717 7.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Haleon2025 3599 – B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Harbin Pharmaceutical Group2000 780 – B 6,455 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 645,531.53" (10,000 CNY) = 6,455.32 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2001 649 -16.8 B 5,370 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 537,001.85" (10,000 CNY) = 5,370.02 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2002 787 21.4 B 6,518 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 651,750.26" (10,000 CNY) = 6,517.50 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2003 838 6.4 B 6,936 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 693,616.66" (10,000 CNY) = 6,936.17 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2004 869 3.7 B 7,191 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 719,118.43" (10,000 CNY) = 7,191.18 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2005 1039 19.6 B 8,510 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 851,036.24" (10,000 CNY) = 8,510.36 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2006 1158 11.4 B 9,228 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"主营业务收入 922,817.96" (10,000 CNY) = 9,228.18 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2007 1090 -5.8 B 8,290 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 829,026.99" (10,000 CNY) = 8,290.27 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2008 1396 28.0 B 9,695 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 969,506.81" (10,000 CNY) = 9,695.07 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2009 1563 12.0 B 10,677 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,067,730.06" (10,000 CNY) = 10,677.30 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2010 1852 18.5 B 12,535 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,253,543.98" (10,000 CNY) = 12,535.44 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2011 2087 12.7 B 13,487 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,348,696.04" (10,000 CNY) = 13,486.96 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2012 2800 34.2 B 17,663 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,766,294.69" (10,000 CNY) = 17,662.95 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2013 2943 5.1 B 18,092 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,809,193.45" (10,000 CNY) = 18,091.93 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2014 2680 -8.9 B 16,509 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,650,891.25" (10,000 CNY) = 16,508.91 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2015 2524 -5.8 B 15,856 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,585,620.78" (10,000 CNY) = 15,856.21 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2016 2128 -15.7 B 14,127 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,412,688.60" (10,000 CNY) = 14,126.89 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2017 1779 -16.4 B 12,018 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入/营业收入 1,201,753.13" (10,000 CNY) = 12,017.53 m
Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump.
Harbin Pharmaceutical Group2018 1638 -7.9 B 10,814 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 108.14亿元" = 10814 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Harbin Pharmaceutical Group2019 1713 4.6 B 11,825 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 118.25亿元" = 11825 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Harbin Pharmaceutical Group2020 1565 -8.7 B 10,788 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 107.88亿元" = 10788 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Harbin Pharmaceutical Group2021 1985 26.9 B 12,802 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 128.02亿元" = 12802 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Harbin Pharmaceutical Group2022 2056 3.6 B 13,809 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 138.09亿元" = 13809 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Harbin Pharmaceutical Group2023 2185 6.3 B 15,457 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 154.57亿元" = 15457 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Harbin Pharmaceutical Group2024 2248 2.9 B 16,176 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 161.76亿元" = 16176 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Harbin Pharmaceutical Group2025 2221 -1.2 B 15,964 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Harbin Pharmaceutical G…Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)
"营业总收入 159.64亿元" = 15964 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Horizon Therapeutics2022 4022 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Hospira2013 2759 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Hospira ... 2,759" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Hospira2014 3035 10.0 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Hospira ... 3,035" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Hospira2015 2131 -29.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Hospira ... 2,131" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Huadong Medicine2000 39 – C 324 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2000-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 162,043.08" (10,000 CNY) = 1,620.43 m x 20% = 324.09 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2001 46 16.5 C 377 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2001-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 188,722.05" (10,000 CNY) = 1,887.22 m x 20% = 377.44 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2002 50 10.6 C 418 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2002-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 208,775.74" (10,000 CNY) = 2,087.76 m x 20% = 417.55 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2003 57 12.5 C 470 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2003-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 234,867.82" (10,000 CNY) = 2,348.68 m x 20% = 469.74 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2004 70 23.6 C 581 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2004-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 290,354.18" (10,000 CNY) = 2,903.54 m x 20% = 580.71 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2005 86 22.0 C 701 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2005-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 350,594.62" (10,000 CNY) = 3,505.95 m x 20% = 701.19 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2006 99 16.2 C 793 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2006-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 396,316.38" (10,000 CNY) = 3,963.16 m x 20% = 792.63 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2007 128 28.4 C 971 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2007-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 485,341.34" (10,000 CNY) = 4,853.41 m x 20% = 970.68 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2008 173 35.7 C 1,203 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2008-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 601,648.61" (10,000 CNY) = 6,016.49 m x 20% = 1,203.30 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2009 229 32.2 C 1,565 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2009-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 782,487.22" (10,000 CNY) = 7,824.87 m x 20% = 1,564.97 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2010 265 15.7 C 1,794 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2010-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 897,183.65" (10,000 CNY) = 8,971.84 m x 20% = 1,794.37 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2011 345 29.9 C 2,226 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2011-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 1,113,137.24" (10,000 CNY) = 11,131.37 m x 20% = 2,226.27 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2012 462 34.2 C 2,916 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2012-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 1,457,923.04" (10,000 CNY) = 14,579.23 m x 20% = 2,915.85 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2013 544 17.7 C 3,344 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2013-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 1,671,798.64" (10,000 CNY) = 16,717.99 m x 20% = 3,343.60 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2014 615 13.1 C 3,789 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2014-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 1,894,737.91" (10,000 CNY) = 18,947.38 m x 20% = 3,789.48 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2015 692 12.4 C 4,345 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2015-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 2,172,738.35" (10,000 CNY) = 21,727.38 m x 20% = 4,345.48 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2016 765 10.5 C 5,076 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2016-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 2,537,966.75" (10,000 CNY) = 25,379.67 m x 20% = 5,075.93 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2017 824 7.8 C 5,566 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2017-12-31
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
"营业收入 2,783,182.31" (10,000 CNY) = 27,831.82 m x 20% = 5,566.36 m
Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015.
Huadong Medicine2018 929 12.7 C 6,133 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
306.63亿 total x 20% = 6132.6 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
Huadong Medicine2019 1027 10.5 C 7,089 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
354.46亿 total x 20% = 7089.2 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
Huadong Medicine2020 977 -4.8 C 6,737 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
336.83亿 total x 20% = 6736.6 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
Huadong Medicine2021 1072 9.7 C 6,913 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
345.63亿 total x 20% = 6912.6 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
Huadong Medicine2022 1123 4.8 C 7,543 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
377.15亿 total x 20% = 7543.0 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
Huadong Medicine2023 1148 2.3 C 8,125 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
406.24亿 total x 20% = 8124.8 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
Huadong Medicine2024 1165 1.4 C 8,381 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
419.06亿 total x 20% = 8381.2 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
Huadong Medicine2025 1214 4.2 C 8,722 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical manufacturing estimated as 20% of total reve…Pharmaceutical manufacturing estimated as 20% of total revenue
436.12亿 total x 20% = 8722.4 RMB m
Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C)
Incyte2022 3747 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Incyte2023 3165 -15.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Incyte2024 3619 14.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Incyte2025 4354 20.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Ipsen2018 2628 – B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ipsen ... 2,628" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Ipsen2019 2884 9.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ipsen ... 2,884" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Ipsen2020 2962 2.7 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Ipsen2021 3236 9.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Ipsen2022 3447 6.5 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Ipsen2023 3555 3.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Ipsen2024 3708 4.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Ipsen2025 4155 12.1 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Jazz Pharmaceuticals2021 3079 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Jazz Pharmaceuticals2022 3634 18.0 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Jazz Pharmaceuticals2023 3737 2.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Jazz Pharmaceuticals2024 3821 2.2 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Jazz Pharmaceuticals2025 4022 5.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Jiangsu Hengrui2000 59 – B 489 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 48,876.18" (10,000 CNY) = 488.76 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2001 77 30.5 B 638 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 63,752.23" (10,000 CNY) = 637.52 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2002 92 18.9 B 758 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 75,823.71" (10,000 CNY) = 758.24 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2003 127 39.0 B 1,054 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 105,433.96" (10,000 CNY) = 1,054.34 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2004 139 9.0 B 1,149 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 114,886.91" (10,000 CNY) = 1,148.87 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2005 145 4.7 B 1,191 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 119,057.55" (10,000 CNY) = 1,190.58 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2006 179 22.9 B 1,423 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"主营业务收入 142,345.61" (10,000 CNY) = 1,423.46 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2007 258 44.3 B 1,960 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 195,966.01" (10,000 CNY) = 1,959.66 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2008 344 33.7 B 2,393 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 239,256.12" (10,000 CNY) = 2,392.56 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2009 443 28.7 B 3,029 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 302,896.09" (10,000 CNY) = 3,028.96 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2010 553 24.7 B 3,744 CNY m phx_hengrui_notes+fx_fed_h10 broker commentary on the annual report
Total revenue (pharma)Total revenue (pharma)
2010A revenue 3,744.11 m
Figures from broker notes surfaced by search (Eastmoney PDFs); the annual reports on sse.com.cn not opened.
Jiangsu Hengrui2011 704 27.3 B 4,550 CNY m phx_hengrui_notes+fx_fed_h10 broker commentary on the annual report
Total revenue (pharma)Total revenue (pharma)
2011 revenue 4.550 bn, +21.53%
Figures from broker notes surfaced by search (Eastmoney PDFs); the annual reports on sse.com.cn not opened.
Jiangsu Hengrui2012 862 22.4 B 5,435 CNY m phx_hengrui_notes+fx_fed_h10 broker commentary on the annual report
Total revenue (pharma)Total revenue (pharma)
2012 revenue 5.435 bn, +19.44%
Figures from broker notes surfaced by search (Eastmoney PDFs); the annual reports on sse.com.cn not opened.
Jiangsu Hengrui2013 1009 17.1 B 6,203 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 620,307.44" (10,000 CNY) = 6,203.07 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2014 1210 19.9 B 7,452 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 745,225.31" (10,000 CNY) = 7,452.25 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2015 1483 22.6 B 9,316 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 931,596.02" (10,000 CNY) = 9,315.96 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2016 1671 12.7 B 11,094 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 1,109,372.41" (10,000 CNY) = 11,093.72 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2017 2049 22.6 B 13,836 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入/营业收入 1,383,562.94" (10,000 CNY) = 13,835.63 m
Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue.
Jiangsu Hengrui2018 2570 25.5 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Hengrui ... 2,570" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Jiangsu Hengrui2019 3321 29.2 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Jiangsu Hengrui Medicine ... 3,321" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Jiangsu Hengrui2020 4022 21.1 B 27,735 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 277.35亿元" = 27735 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Jiangsu Hengrui2021 4017 -0.1 B 25,906 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 259.06亿元" = 25906 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Jiangsu Hengrui2022 3167 -21.1 B 21,275 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 212.75亿元" = 21275 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Jiangsu Hengrui2023 3225 1.8 B 22,820 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 228.20亿元" = 22820 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Jiangsu Hengrui2024 3889 20.6 B 27,985 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 279.85亿元" = 27985 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Jiangsu Hengrui2025 4401 13.2 B 31,629 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (almost entirely pharma…Total revenue of the listed company (almost entirely pharmaceutical)
"营业总收入 316.29亿元" = 31629 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Johnson & Johnson2000 9500 – C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2001 11100 16.8 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2002 13100 18.0 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2003 15300 16.8 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2004 17500 14.4 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2005 20300 16.0 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2006 23300 14.8 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2007 24600 5.6 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2008 24590 0.0 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
22500 / (1-8.5%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Johnson & Johnson2009 22500 -8.5 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
jnj 22.5 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Johnson & Johnson2010 22400 -0.4 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2011 24400 8.9 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
jnj $24.4 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Johnson & Johnson2012 25400 4.1 C phx_est selected data / segment note
Pharmaceutical segment salesPharmaceutical segment sales
J&J 10-K segment note, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Johnson & Johnson2013 26475 4.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 26,475" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Johnson & Johnson2014 30726 16.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 30,726" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Johnson & Johnson2015 29864 -2.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 29,864" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Johnson & Johnson2016 31671 6.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 31,671" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Johnson & Johnson2017 34397 8.6 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 34,397" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Johnson & Johnson2018 38815 12.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson & Johnson ... 38,815" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Johnson & Johnson2019 40083 3.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Johnson &Johnson ... 40,083" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Johnson & Johnson2020 43149 7.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Johnson & Johnson2021 49821 15.5 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Johnson & Johnson2022 50179 0.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Johnson & Johnson2023 53463 6.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Johnson & Johnson2024 55745 4.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Johnson & Johnson2025 59331 6.4 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Kyowa Kirin2010 3165 – C 277,204 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Pharmaceutical revenue estimate = group net sales x 0.67Pharmaceutical revenue estimate = group net sales x 0.67
group net sales 413,738 x 0.67
Share 0.67 calibrated to the Pharm Exec 2014 row for 2013 (2,334 US$ m x 97.6 = 228 bn / 341 bn); the group includes Kyowa Hakko Bio and chemicals. Kyowa Hakko Kirin formed Oct 2008; the 9-month transition period 2009 is left out. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Kyowa Kirin2011 2892 -8.6 C 230,294 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Pharmaceutical revenue estimate = group net sales x 0.67Pharmaceutical revenue estimate = group net sales x 0.67
group net sales 343,722 x 0.67
Share 0.67 calibrated to the Pharm Exec 2014 row for 2013 (2,334 US$ m x 97.6 = 228 bn / 341 bn); the group includes Kyowa Hakko Bio and chemicals. Kyowa Hakko Kirin formed Oct 2008; the 9-month transition period 2009 is left out. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Kyowa Kirin2012 2798 -3.2 C 223,216 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Pharmaceutical revenue estimate = group net sales x 0.67Pharmaceutical revenue estimate = group net sales x 0.67
group net sales 333,158 x 0.67
Share 0.67 calibrated to the Pharm Exec 2014 row for 2013 (2,334 US$ m x 97.6 = 228 bn / 341 bn); the group includes Kyowa Hakko Bio and chemicals. Kyowa Hakko Kirin formed Oct 2008; the 9-month transition period 2009 is left out. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Kyowa Kirin2013 2334 -16.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Kyowa Hakko Kirin ... 2,334" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Kyowa Kirin2014 2157 -7.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Kyowa Hakko Kirin ... 2,157" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Kyowa Kirin2016 2228 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Kyowa Hakko Kirin ... 2,228" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Kyowa Kirin2017 2272 2.0 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Kyowa Hakko Kirin ... 2,272" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Kyowa Kirin2021 2959 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Livzon Pharmaceutical Group2000 143 – B 1,182 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 118,205.67" (10,000 CNY) = 1,182.06 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2001 170 19.2 B 1,409 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 140,930.66" (10,000 CNY) = 1,409.31 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2002 195 14.7 B 1,616 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 161,642.92" (10,000 CNY) = 1,616.43 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2003 220 12.4 B 1,818 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 181,765.67" (10,000 CNY) = 1,817.66 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2004 189 -14.2 B 1,560 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 156,030.81" (10,000 CNY) = 1,560.31 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2005 199 5.5 B 1,629 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 162,890.62" (10,000 CNY) = 1,628.91 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2006 190 -4.4 B 1,515 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"主营业务收入 151,516.14" (10,000 CNY) = 1,515.16 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2007 230 21.0 B 1,748 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 174,810.84" (10,000 CNY) = 1,748.11 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2008 296 28.9 B 2,059 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 205,864.06" (10,000 CNY) = 2,058.64 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2009 380 28.2 B 2,596 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 259,584.71" (10,000 CNY) = 2,595.85 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2010 403 6.0 B 2,727 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 272,671.89" (10,000 CNY) = 2,726.72 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2011 489 21.5 B 3,163 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 316,291.53" (10,000 CNY) = 3,162.92 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2012 625 27.7 B 3,944 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 394,352.53" (10,000 CNY) = 3,943.53 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2013 751 20.2 B 4,619 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 461,868.00" (10,000 CNY) = 4,618.68 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2014 900 19.8 B 5,544 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 554,423.38" (10,000 CNY) = 5,544.23 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2015 1054 17.1 B 6,621 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 662,051.65" (10,000 CNY) = 6,620.52 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2016 1153 9.4 B 7,652 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 765,177.53" (10,000 CNY) = 7,651.78 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2017 1263 9.6 B 8,531 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入/营业收入 853,096.86" (10,000 CNY) = 8,530.97 m
Sina Finance table for stock 000513. Pre-2007 line is main business revenue.
Livzon Pharmaceutical Group2018 1342 6.3 B 8,861 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 88.61亿元" = 8861 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Livzon Pharmaceutical Group2019 1359 1.3 B 9,385 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 93.85亿元" = 9385 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Livzon Pharmaceutical Group2020 1526 12.2 B 10,520 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 105.20亿元" = 10520 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Livzon Pharmaceutical Group2021 1871 22.6 B 12,064 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 120.64亿元" = 12064 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Livzon Pharmaceutical Group2022 1880 0.5 B 12,630 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 126.30亿元" = 12630 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Livzon Pharmaceutical Group2023 1757 -6.6 B 12,430 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 124.30亿元" = 12430 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Livzon Pharmaceutical Group2024 1642 -6.6 B 11,812 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 118.12亿元" = 11812 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Livzon Pharmaceutical Group2025 1672 1.9 B 12,020 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Livzon Pharmaceutical G…Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)
"营业总收入 120.20亿元" = 12020 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Lundbeck2000 297 – C 2,400 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2001 372 25.2 C 3,100 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2002 458 23.0 C 3,600 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3600 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2003 655 43.0 C 4,300 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4300 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2004 836 27.7 C 5,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2005 1002 19.9 C 6,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2006 1196 19.3 C 7,100 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7100 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2007 1509 26.2 C 8,200 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 8200 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2008 1913 26.8 C 9,700 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9700 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2009 2208 15.4 C 11,800 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11800 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2010 2442 10.6 C 13,700 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 13700 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2011 2914 19.3 C 15,600 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15600 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2012 2938 0.8 C 17,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pure-play pharma)Total revenue (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Lundbeck2013 2431 -17.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Lundbeck ... 2,431" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Lundbeck2014 2223 -8.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Lundbeck ... 2,223" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Lupin2016 2490 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Lupin ... 2,490" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Lupin2017 2344 -5.9 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Lupin ... 2,344" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Mallinckrodt2014 2310 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 2,310" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Mallinckrodt2015 2976 28.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 2,976" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Mallinckrodt2016 2918 -1.9 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 2,918" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Mallinckrodt2017 3141 7.6 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 3,141" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Mallinckrodt2018 2543 -19.0 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mallinckrodt ... 2,543" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Meda2015 2139 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Meda ... 2,139" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Meiji Seika Pharma2019 6353 – B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Meiji Holdings ... 6,353" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Menarini2000 1016 – C 1,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2001 1075 5.8 C 1,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2002 1229 14.4 C 1,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2003 1584 28.9 C 1,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2004 1866 17.8 C 1,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2005 1991 6.7 C 1,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2006 2135 7.2 C 1,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2007 2468 15.6 C 1,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2008 3235 31.1 C 2,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2009 3344 3.4 C 2,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2010 3717 11.2 C 2,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2011 4176 12.3 C 3,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2012 4116 -1.4 C 3,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Menarini2013 3324 -19.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,324" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Menarini2014 3442 3.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,442" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Menarini2015 2836 -17.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 2,836" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Menarini2016 2916 2.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 2,916" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Menarini2017 3072 5.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,072" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Menarini2018 3313 7.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,313" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Menarini2019 3233 -2.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Menarini ... 3,233" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Menarini2020 3465 7.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Menarini2021 3616 4.4 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Menarini2022 3621 0.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Menarini2023 3840 6.0 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Menarini2024 4006 4.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Menarini2025 4358 8.8 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Merck & Co.2000 19700 – C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Merck & Co.2001 21200 7.6 C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Merck & Co.2002 21446 1.2 B phx_sec_mrk2006 FY2006 10-K Item 6 selected financial data
Total sales (Merck Rx incl. vaccines; Medco spun off Aug 20…Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 21,445.8
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
Merck & Co.2003 22486 4.8 B phx_sec_mrk2006 FY2005 Exhibit 13 income statement
Total sales (Merck Rx incl. vaccines; Medco spun off Aug 20…Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 22,485.9
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
Merck & Co.2004 22939 2.0 B phx_sec_mrk2006 FY2005 Exhibit 13 income statement
Total sales (Merck Rx incl. vaccines; Medco spun off Aug 20…Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 22,938.6
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
Merck & Co.2005 22012 -4.0 B phx_sec_mrk2006 FY2006 10-K Item 1 product sales table
Total sales (Merck Rx incl. vaccines; Medco spun off Aug 20…Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 22,011.9
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
Merck & Co.2006 22636 2.8 B phx_sec_mrk2006 FY2006 10-K Item 1 product sales table
Total sales (Merck Rx incl. vaccines; Medco spun off Aug 20…Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)
Sales 22,636.0
Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8)
Merck & Co.2007 24200 6.9 C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Merck & Co.2008 23570 -2.6 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
25200 / (1+6.9%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Merck & Co.2009 25200 6.9 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
merck 25.2 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn; Merck includes Schering-Plough from Nov 2009
Merck & Co.2010 39500 56.7 C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Merck & Co.2011 41300 4.6 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
merck $41.3 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Merck & Co.2012 40500 -1.9 C phx_est selected data / segment note
Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-Medco
Merck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Merck & Co.2013 37519 -7.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 37,519" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Merck & Co.2014 36607 -2.4 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 36,607" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Merck & Co.2015 35244 -3.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 35,244" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Merck & Co.2016 35563 0.9 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 35,563" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Merck & Co.2017 35370 -0.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 35,370" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Merck & Co.2018 37353 5.6 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 37,353" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Merck & Co.2019 40903 9.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck & Co. ... 40,903" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Merck & Co.2020 41435 1.3 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Merck & Co.2021 43259 4.4 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Merck & Co.2022 49627 14.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Merck & Co.2023 50846 2.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Merck & Co.2024 54314 6.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Merck & Co.2025 54685 0.7 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Merck KGaA2000 1754 – C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2001 1881 7.2 C 2,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2002 2269 20.6 C 2,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2003 2716 19.7 C 2,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2004 3358 23.7 C 2,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2005 3485 3.8 C 2,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2006 3642 4.5 C 2,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2007 7814 114.5 C 5,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2008 8823 12.9 C 6,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2009 8499 -3.7 C 6,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2010 9028 6.2 C 6,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2011 10023 11.0 C 7,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2012 9648 -3.7 C 7,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono f…Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Merck KGaA2013 7913 -18.0 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,913" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Merck KGaA2014 7683 -2.9 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,683" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Merck KGaA2015 7693 0.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,693" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Merck KGaA2016 6633 -13.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 6,633" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Merck KGaA2017 6880 3.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 6,880" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Merck KGaA2018 7001 1.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,001" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Merck KGaA2019 7516 7.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Merck KGaA ... 7,516" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Merck KGaA2020 7579 0.8 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Merck KGaA2021 8392 10.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Merck KGaA2022 8366 -0.3 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Merck KGaA2023 8711 4.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Merck KGaA2024 9148 5.0 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Merck KGaA2025 9728 6.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Mitsubishi Chemical Group2023 4235 – B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Mitsubishi Tanabe2012 3505 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 3,505" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Mitsubishi Tanabe2014 2928 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,928" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Mitsubishi Tanabe2015 2542 -13.2 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,542" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Mitsubishi Tanabe2016 2696 6.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,696" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Mitsubishi Tanabe2017 2581 -4.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,581" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Mitsubishi Tanabe2018 2913 12.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe ... 2,913" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Mitsubishi Tanabe2019 2822 -3.1 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mitsubishi Tanabe Pharma ... 2,822" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Mitsubishi Tanabe2020 3106 10.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Mitsubishi Tanabe Pharma2005 3607 – B 407,800 JPY m phx_mtpc+fx_fed_h10 article text
Combined sales of Mitsubishi Pharma + Tanabe Seiyaku (pro f…Combined sales of Mitsubishi Pharma + Tanabe Seiyaku (pro forma, practically all pharma)
combined sales totaled 407.8 billion yen in the year to March 2006
Seen only as a search snippet; the two merged in Oct 2007.
Mitsubishi Tanabe Pharma2011 5160 – B 407,156 JPY m phx_mtpc_credit+fx_fed_h10 credit report text
Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)
Yen 419,179 million, 3% up from Yen 407,156 million in the previous term
Third-party credit report (snippet); FY2007-2010 not found.
Moderna2021 19167 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Moderna2022 18435 -3.8 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Moderna2023 6671 -63.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Moderna2024 3218 -51.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Mylan2008 4310 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
4800 / (1+11.4%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Mylan2009 4800 11.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
mylan 4.8 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Mylan2010 5450 13.5 C phx_est selected data / segment note
Total revenues (generics)Total revenues (generics)
Mylan total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Mylan2011 5500 0.9 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
mylan $5.5 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Mylan2012 6800 23.6 C phx_est selected data / segment note
Total revenues (generics)Total revenues (generics)
Mylan total revenues
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Mylan2013 6772 -0.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 25
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 6,772" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Mylan2014 7585 12.0 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 24
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 7,585" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Mylan2015 9291 22.5 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 9,291" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Mylan2016 10839 16.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 23
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 10,839" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Mylan2017 11454 5.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 11,454" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Mylan2018 11144 -2.7 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 11,144" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Mylan2019 11200 0.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Mylan ... 11,200" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Nestlé Health Science2015 2431 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Nestle ... 2,431" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
North China Pharmaceutical2000 286 – B 2,369 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 236,882.01" (10,000 CNY) = 2,368.82 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2001 348 21.7 B 2,882 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 288,171.11" (10,000 CNY) = 2,881.71 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2002 372 6.7 B 3,076 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 307,610.49" (10,000 CNY) = 3,076.10 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2003 435 17.1 B 3,604 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 360,366.12" (10,000 CNY) = 3,603.66 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2004 502 15.3 B 4,155 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 415,542.72" (10,000 CNY) = 4,155.43 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2005 487 -3.1 B 3,987 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 398,713.91" (10,000 CNY) = 3,987.14 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2006 455 -6.6 B 3,624 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"主营业务收入 362,401.93" (10,000 CNY) = 3,624.02 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2007 558 22.7 B 4,241 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 424,058.71" (10,000 CNY) = 4,240.59 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2008 707 26.8 B 4,911 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 491,095.71" (10,000 CNY) = 4,910.96 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2009 715 1.1 B 4,883 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 488,252.21" (10,000 CNY) = 4,882.52 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2010 1520 112.6 B 10,287 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 1,028,664.34" (10,000 CNY) = 10,286.64 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2011 1878 23.6 B 12,137 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 1,213,674.57" (10,000 CNY) = 12,136.75 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2012 1764 -6.1 B 11,126 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 1,112,570.62" (10,000 CNY) = 11,125.71 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2013 2023 14.7 B 12,438 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 1,243,814.37" (10,000 CNY) = 12,438.14 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2014 1526 -24.6 B 9,401 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 940,097.27" (10,000 CNY) = 9,400.97 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2015 1258 -17.6 B 7,902 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 790,250.23" (10,000 CNY) = 7,902.50 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2016 1217 -3.2 B 8,082 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 808,246.28" (10,000 CNY) = 8,082.46 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2017 1141 -6.2 B 7,709 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入/营业收入 770,912.19" (10,000 CNY) = 7,709.12 m
Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue.
North China Pharmaceutical2018 1396 22.3 B 9,214 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 92.14亿元" = 9214 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
North China Pharmaceutical2019 1659 18.9 B 11,457 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 114.57亿元" = 11457 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
North China Pharmaceutical2020 1667 0.4 B 11,493 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 114.93亿元" = 11493 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
North China Pharmaceutical2021 1610 -3.4 B 10,385 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 103.85亿元" = 10385 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
North China Pharmaceutical2022 1563 -2.9 B 10,500 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 105.00亿元" = 10500 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
North China Pharmaceutical2023 1430 -8.5 B 10,120 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 101.20亿元" = 10120 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
North China Pharmaceutical2024 1372 -4.1 B 9,870 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 98.70亿元" = 9870 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
North China Pharmaceutical2025 1286 -6.3 B 9,242 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (antibiotics, vitamins,…Total revenue of the listed company (antibiotics, vitamins, formulations)
"营业总收入 92.42亿元" = 9242 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Novartis2000 11000 – C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2001 12300 11.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 12300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2002 14000 13.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 14000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2003 17500 25.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2004 19800 13.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 19800 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2005 22400 13.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 22400 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2006 27300 21.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2007 32646 19.6 B phx_nov20f2007 Item 4 principal markets tables
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Pharmaceuticals 24,025 + Sandoz 7,169 + Vaccines and Diagnostics 1,452 = 32,646 (US$ m)
Sum of three divisions from the 20-F FY2007
Novartis2008 35500 8.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 35500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2009 38000 7.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 38000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2010 41000 7.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 41000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2011 44000 7.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 44000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2012 44500 1.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ne…Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 44500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novartis2013 46017 3.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 46,017" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Novartis2014 46127 0.2 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 46,127" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Novartis2015 42467 -7.9 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 42,467" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Novartis2016 41554 -2.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 41,554" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Novartis2017 41875 0.8 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 41,875" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Novartis2018 43481 3.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 43,481" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Novartis2019 46085 6.0 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novartis ... 46,085" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Novartis2020 47202 2.4 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Novartis2021 51128 8.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Novartis2022 50079 -2.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Novartis2023 52473 4.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Novartis2024 50191 -4.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Novartis2025 54332 8.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Novavax2022 1555 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Novo Nordisk2000 2218 – C 17,900 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17900 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2001 2607 17.5 C 21,700 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 21700 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2002 3091 18.6 C 24,300 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24300 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2003 4020 30.1 C 26,400 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 26400 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2004 4731 17.7 C 28,300 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 28300 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2005 5262 11.2 C 31,500 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 31500 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2006 5894 12.0 C 35,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 35000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2007 7121 20.8 C 38,700 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 38700 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2008 8873 24.6 C 45,000 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 45000 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2009 9556 7.7 C 51,078 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 51078 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2010 10833 13.4 C 60,776 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 60776 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2011 12394 14.4 C 66,346 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 66346 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2012 13483 8.8 C 78,026 DKK m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total net sales (pure-play pharma)Total net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 78026 DKK m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Novo Nordisk2013 14886 10.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 14,886" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Novo Nordisk2014 15825 6.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 15,825" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Novo Nordisk2015 16054 1.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 16,054" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Novo Nordisk2016 16610 3.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 16,610" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Novo Nordisk2017 16971 2.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 16,971" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Novo Nordisk2018 17726 4.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 15
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 17,726" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Novo Nordisk2019 18296 3.2 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Novo Nordisk ... 18,296" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Novo Nordisk2020 19444 6.3 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Novo Nordisk2021 22417 15.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Novo Nordisk2022 25384 13.2 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Novo Nordisk2023 33722 32.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Novo Nordisk2024 42122 24.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Novo Nordisk2025 46801 11.1 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Ono2001 1046 – C 130,686 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 133,353 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2002 1086 3.8 C 132,293 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 134,993 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2003 1212 11.5 C 136,595 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 139,383 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2004 1326 9.4 C 142,396 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 145,302 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2005 1289 -2.8 C 145,698 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 148,671 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2006 1188 -7.8 C 138,877 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 141,711 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2007 1256 5.7 C 142,979 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 145,897 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2008 1337 6.5 C 133,825 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 136,556 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2009 1437 7.4 C 133,266 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 135,986 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2010 1551 7.9 C 132,550 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 135,255 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2011 1810 16.7 C 142,862 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.98
group net sales 145,778 x 0.98
Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Ono2016 2153 – B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ono ... 2,153" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Ono2017 2363 9.8 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ono ... 2,363" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Ono2019 3266 – B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ono Pharmaceutical ... 3,266" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Ono2020 2908 -11.0 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Organon2021 6172 – B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Organon2022 6038 -2.2 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Organon2023 6142 1.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Organon2024 6219 1.3 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Organon2025 6060 -2.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Otsuka2002 2686 – C 327,129 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 474,100 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2003 2991 11.4 C 337,203 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 488,700 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2004 4392 46.8 C 471,822 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 683,800 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2005 4596 4.6 C 519,639 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 753,100 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2006 5039 9.6 C 589,191 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 853,900 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2007 5627 11.7 C 640,596 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 928,400 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2008 6591 17.1 C 659,571 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 955,900 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2009 8066 22.4 C 748,161 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 1,084,291 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2010 9103 12.9 C 778,036 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 1,127,589 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2011 10096 10.9 C 796,655 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Prescription pharmaceutical revenue estimate = group net sa…Prescription pharmaceutical revenue estimate = group net sales x 0.69
group net sales 1,154,573 x 0.69
Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Otsuka2012 8655 -14.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 8,655" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Otsuka2014 6961 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 6,961" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Otsuka2015 6728 -3.3 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 27
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 6,728" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Otsuka2016 5389 -19.9 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 5,389" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Otsuka2017 5324 -1.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 5,324" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Otsuka2018 5726 7.6 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 28
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka ... 5,726" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Otsuka2019 6711 17.2 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 26
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Otsuka Holdings ... 6,711" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Otsuka2020 7219 7.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Otsuka2021 7368 2.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Otsuka2022 7357 -0.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Otsuka2023 7970 8.3 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Otsuka2024 8975 12.6 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Otsuka2025 9869 10.0 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Perrigo2022 5436 – B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Pfizer2000 24400 – C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less consum…Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Pfizer2001 26800 9.8 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less consum…Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Pfizer2002 27100 1.1 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less consum…Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Pfizer2003 39425 45.5 B phx_sec_pfe2005 Financial Review, Human Health revenue table p.12
Human Health segment revenues (includes Pharmacia from Apr …Human Health segment revenues (includes Pharmacia from Apr 2003)
Human Health 2003 39,425 (total revenues 44,736)
Pfizer 2005 Financial Report (Exhibit 13 to FY2005 10-K)
Pfizer2004 46133 17.0 B phx_sec_pfe2005 Financial Review, Human Health revenue table p.12
Human Health segment revenuesHuman Health segment revenues
Human Health 2004 46,133 (total revenues 52,516)
Pfizer 2005 Financial Report (Exhibit 13 to FY2005 10-K)
Pfizer2005 44284 -4.0 B phx_sec_pfe2005 Financial Review, Human Health revenue table p.12
Human Health segment revenuesHuman Health segment revenues
Human Health 2005 44,284 (total revenues 51,298)
Pfizer 2005 Financial Report (Exhibit 13 to FY2005 10-K)
Pfizer2006 45100 1.8 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less consum…Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Pfizer2007 44400 -1.6 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less consum…Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Pfizer2008 44210 -0.4 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
45400 / (1+2.7%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Pfizer2009 45400 2.7 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
pfizer 45.4 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn; Pfizer excludes Wyeth, which is its own entity until absorbed
Pfizer2010 58500 28.9 B phx_pe2011 Pharm Exec 50 (2011): Pfizer 2010 Rx sales
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
"grew from $45.4 billion in Rx sales to $58.5 billion"
2010 includes Wyeth; read from a search-result summary of the 12th Pharm Exec 50 (page not retrievable)
Pfizer2011 57700 -1.4 B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
pfizer $57.7 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Pfizer2012 48000 -16.8 C phx_est selected data / segment note
Pharmaceutical segment, approx. (total revenues less consum…Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)
Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Pfizer2013 45011 -6.2 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 45,011" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Pfizer2014 44514 -1.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 44,514" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Pfizer2015 43112 -3.1 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 43,112" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Pfizer2016 45906 6.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 45,906" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Pfizer2017 45345 -1.2 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 45,345" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Pfizer2018 45302 -0.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 45,302" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Pfizer2019 43662 -3.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Pfizer ... 43,662" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Pfizer2020 35608 -18.4 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Pfizer2021 72043 102.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Pfizer2022 91303 26.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Pfizer2023 48218 -47.2 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Pfizer2024 51953 7.7 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Pfizer2025 49909 -3.9 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Pharmacia2000 15000 – C phx_est selected data / segment note
Pharmaceutical sales (Pharmacia incl. Searle; merged into P…Pharmaceutical sales (Pharmacia incl. Searle; merged into Pfizer Apr 2003)
Pharmacia sales excl. consumer healthcare and animal health, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Pharmacia2001 14300 -4.7 C phx_est selected data / segment note
Pharmaceutical sales (Pharmacia incl. Searle; merged into P…Pharmaceutical sales (Pharmacia incl. Searle; merged into Pfizer Apr 2003)
Pharmacia sales excl. consumer healthcare and animal health, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Pharmacia2002 13800 -3.5 C phx_est selected data / segment note
Pharmaceutical sales (Pharmacia incl. Searle; merged into P…Pharmaceutical sales (Pharmacia incl. Searle; merged into Pfizer Apr 2003)
Pharmacia sales excl. consumer healthcare and animal health, approximated
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Purdue Pharma2013 2217 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Purdue ... 2,217" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Ranbaxy2008 1678 – B 72,414 INR m phx_rbx_press+fx_fed_h10 results notice
Consolidated net sales (pharma)Consolidated net sales (pharma)
Net Sales Rs 724140.7 lacs for 2008
2008 and 2011 via search snippets only. 2009 restated in AR2010 (73,294 in the earlier release). December year-end.
Ranbaxy2009 1521 -9.4 A 73,441 INR m phx_rbx_ar2010+fx_fed_h10 Directors report, consolidated sales
Consolidated net sales (pharma)Consolidated net sales (pharma)
Rs. 85,507 millions against Rs.73,441 millions in the previous year
December year-end. The AR2010 ten-year table gives the standalone company only (2001-2010), not used.
Ranbaxy2010 1874 23.2 A 85,507 INR m phx_rbx_ar2010+fx_fed_h10 Directors report, consolidated sales
Consolidated net sales (pharma)Consolidated net sales (pharma)
consolidated sales of Rs. 85,507 millions
December year-end. The AR2010 ten-year table gives the standalone company only (2001-2010), not used.
Ranbaxy2011 2147 14.6 B 99,769 INR m phx_rbx_press+fx_fed_h10 results notice
Consolidated net sales (pharma)Consolidated net sales (pharma)
consolidated sales Rs 99,769 Mn
2008 and 2011 via search snippets only. 2009 restated in AR2010 (73,294 in the earlier release). December year-end.
Ranbaxy2012 2199 2.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 50
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Ranbaxy ... 2,199" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Regeneron2015 2689 – B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 44
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 2,689" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Regeneron2016 3338 24.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 3,338" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Regeneron2017 3718 11.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 3,718" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Regeneron2018 4106 10.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 38
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 4,106" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Regeneron2019 4834 17.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Regeneron ... 4,834" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Regeneron2020 5568 15.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Regeneron2021 12117 117.6 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Regeneron2022 6894 -43.1 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Regeneron2023 7078 2.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Regeneron2024 7629 7.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Regeneron2025 6309 -17.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Roche2000 8946 – C 15,100 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15100 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2001 10139 13.3 C 17,100 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17100 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2002 12178 20.1 C 18,900 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18900 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2003 13911 14.2 C 18,700 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18700 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2004 16514 18.7 C 20,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 20500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2005 19690 19.2 C 24,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2006 23548 19.6 C 29,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 29500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2007 28362 20.4 C 34,000 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 34000 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2008 33791 19.1 C 36,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 36500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2009 35345 4.6 C 38,300 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 38300 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2010 35096 -0.7 C 36,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 36500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2011 37869 7.9 C 33,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2012 37888 0.0 C 35,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 35500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Roche2013 39143 3.3 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 39,143" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Roche2014 40086 2.4 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 40,086" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Roche2015 38733 -3.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 38,733" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Roche2016 39552 2.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 39,552" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Roche2017 41732 5.5 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 3
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 41,732" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Roche2018 44552 6.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 2
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 44,552" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Roche2019 48247 8.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 1
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Roche ... 48,247" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Roche2020 47492 -1.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Roche2021 49293 3.8 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Roche2022 47909 -2.8 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Roche2023 49110 2.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Roche2024 52457 6.8 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Roche2025 57514 9.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Sandoz2023 9647 – B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Sandoz2024 10357 7.4 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Sandoz2025 11086 7.0 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Sankyo2004 4051 – B 435,140 JPY m phx_dsc_pres+phx_daiichi_20f+fx_fed_h10 Daiichi Sankyo merger presentation, FY2004 combined pharma figure
Pharmaceutical net sales: combined Sankyo + Daiichi Pharmac…Pharmaceutical net sales: combined Sankyo + Daiichi Pharmaceutical (760 bn yen) minus Daiichi Pharmaceutical (324.9 bn)
760,000 - 324,860 = 435,140; Sankyo total net sales 587,830 incl. non-pharma
The 760 bn combined figure was quoted in a search result for a Daiichi Sankyo investor presentation; document not opened.
Sanofi2004 17787 – C 14,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. An…Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 14300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi2005 33606 88.9 C 27,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. An…Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi2006 35544 5.8 C 28,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. An…Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 28300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi2007 38385 8.0 C 28,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. An…Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 28000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi2008 39702 3.4 C 27,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. An…Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi2009 40822 2.8 C 29,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. An…Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 29300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi2010 40359 -1.1 C 30,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. An…Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 30400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi2011 46494 15.2 C 33,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. An…Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi2012 44894 -3.4 C 34,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. An…Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 34900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi2013 37701 -16.0 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 37,701" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Sanofi2014 38223 1.4 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 4
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 38,223" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Sanofi2015 34896 -8.7 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 34,896" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Sanofi2016 34174 -2.1 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 5
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 34,174" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Sanofi2017 34078 -0.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 34,078" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Sanofi2018 35121 3.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 6
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 35,121" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Sanofi2019 34924 -0.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 7
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sanofi ... 34,924" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Sanofi2020 35802 2.5 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Sanofi2021 38934 8.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Sanofi2022 40353 3.6 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Sanofi2023 40805 1.1 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Sanofi2024 44243 8.4 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Sanofi2025 48971 10.7 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Sanofi-Synthelabo2000 4155 – C 4,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi-Synthelabo2001 4836 16.4 C 5,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi-Synthelabo2002 6145 27.1 C 6,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Sanofi-Synthelabo2003 8375 36.3 C 7,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Schering AG2000 2863 – C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acquire…Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Schering AG2001 3134 9.5 C 3,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acquire…Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Schering AG2002 3876 23.7 C 4,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acquire…Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Schering AG2003 4980 28.5 C 4,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acquire…Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Schering AG2004 5971 19.9 C 4,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acquire…Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Schering AG2005 6597 10.5 C 5,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Schering AG total net sales (pharma pure-play, 2006 acquire…Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Schering-Plough2000 8500 – C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Schering-Plough2001 8600 1.2 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Schering-Plough2002 9100 5.8 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Schering-Plough2003 7300 -19.8 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Schering-Plough2004 7300 0.0 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Schering-Plough2005 8500 16.4 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Schering-Plough2006 9500 11.8 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Schering-Plough2007 11000 15.8 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Schering-Plough2008 13500 22.7 C phx_est selected data / segment note
Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)
Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Serono2000 770 – C 1,300 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acquire…Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Serono2001 949 23.2 C 1,600 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acquire…Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1600 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Serono2002 1160 22.3 C 1,800 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acquire…Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Serono2003 1637 41.1 C 2,200 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acquire…Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2200 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Serono2004 1933 18.1 C 2,400 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acquire…Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Serono2005 2009 3.9 C 2,500 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acquire…Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2500 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Serono2006 2155 7.3 C 2,700 CHF m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Serono SA total revenues (pure-play biotech/pharma; acquire…Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2700 CHF m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2000 2216 – C 2,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2001 2328 5.1 C 2,600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2002 2647 13.7 C 2,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2003 3395 28.3 C 3,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2004 3980 17.2 C 3,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2005 4232 6.3 C 3,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2006 4647 9.8 C 3,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2007 5347 15.0 C 3,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2008 6029 12.8 C 4,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2009 5434 -9.9 C 3,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2010 5178 -4.7 C 3,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2011 5707 10.2 C 4,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2012 5403 -5.3 C 4,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Servier2013 5058 -6.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 5,058" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Servier2014 5999 18.6 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 5,999" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Servier2015 4470 -25.5 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 4,470" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Servier2016 4167 -6.8 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 4,167" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Servier2017 4566 9.6 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 4,566" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Servier2018 5103 11.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Servier ... 5,103" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Servier2019 4658 -8.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"LES LABORATOIRES SERVIER ... 4,658" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Servier2020 5155 10.7 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Servier2021 4344 -15.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Servier2022 5193 19.5 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Servier2023 5113 -1.5 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Servier2024 5262 2.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Servier2025 5440 3.4 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Shanghai Pharmaceuticals2000 83 – C 690 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2000-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 460,072.38" (10,000 CNY) = 4,600.72 m x 15% = 690.11 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2001 94 13.3 C 782 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2001-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 521,059.32" (10,000 CNY) = 5,210.59 m x 15% = 781.59 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2002 131 39.1 C 1,088 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2002-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 725,045.56" (10,000 CNY) = 7,250.46 m x 15% = 1,087.57 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2003 178 35.2 C 1,470 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2003-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 980,255.52" (10,000 CNY) = 9,802.56 m x 15% = 1,470.38 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2004 197 10.6 C 1,627 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2004-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,084,383.04" (10,000 CNY) = 10,843.83 m x 15% = 1,626.57 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2005 196 -0.1 C 1,608 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2005-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,072,286.69" (10,000 CNY) = 10,722.87 m x 15% = 1,608.43 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2006 238 21.1 C 1,896 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2006-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,263,916.73" (10,000 CNY) = 12,639.17 m x 15% = 1,895.88 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2007 275 15.5 C 2,088 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2007-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,391,979.12" (10,000 CNY) = 13,919.79 m x 15% = 2,087.97 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2008 357 30.1 C 2,482 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2008-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,654,782.49" (10,000 CNY) = 16,547.82 m x 15% = 2,482.17 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2009 430 20.2 C 2,935 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2009-12-31
Pharmaceutical industry arm estimated as 15% of consolidate…Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)
"营业收入 1,956,812.38" (10,000 CNY) = 19,568.12 m x 15% = 2,935.22 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2010 663 54.4 C 4,489 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2010-12-31
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 3,741,106.61" (10,000 CNY) = 37,411.07 m x 12% = 4,489.33 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2011 1019 53.7 C 6,588 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2011-12-31
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 5,489,987.25" (10,000 CNY) = 54,899.87 m x 12% = 6,587.98 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2012 1295 27.0 C 8,169 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2012-12-31
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 6,807,811.78" (10,000 CNY) = 68,078.12 m x 12% = 8,169.37 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2013 1527 17.9 C 9,387 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2013-12-31
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 7,822,281.74" (10,000 CNY) = 78,222.82 m x 12% = 9,386.74 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2014 1800 17.9 C 11,088 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2014-12-31
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 9,239,889.36" (10,000 CNY) = 92,398.89 m x 12% = 11,087.87 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2015 2016 12.0 C 12,662 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2015-12-31
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 10,551,658.73" (10,000 CNY) = 105,516.59 m x 12% = 12,661.99 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2016 2183 8.3 C 14,492 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2016-12-31
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 12,076,466.03" (10,000 CNY) = 120,764.66 m x 12% = 14,491.76 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2017 2325 6.5 C 15,702 CNY m phx_cn_sina+phx_cn_est+fx_fed_h10 Sina Finance income statement 2017-12-31
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
"营业收入 13,084,718.19" (10,000 CNY) = 130,847.18 m x 12% = 15,701.66 m
Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read.
Shanghai Pharmaceuticals2018 2891 24.4 C 19,090 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
1590.84亿 total x 12% = 19090.1 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
Shanghai Pharmaceuticals2019 2875 -0.6 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shanghai Pharmaceuticals Holding ... 2,875" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Shanghai Pharmaceuticals2020 3340 16.2 C 23,029 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
1919.09亿 total x 12% = 23029.1 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
Shanghai Pharmaceuticals2021 4016 20.2 C 25,899 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2158.24亿 total x 12% = 25898.9 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
Shanghai Pharmaceuticals2022 4144 3.2 C 27,838 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2319.81亿 total x 12% = 27837.7 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
Shanghai Pharmaceuticals2023 4415 6.5 C 31,235 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2602.95亿 total x 12% = 31235.4 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
Shanghai Pharmaceuticals2024 4591 4.0 C 33,030 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2752.51亿 total x 12% = 33030.1 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
Shanghai Pharmaceuticals2025 4735 3.1 C 34,030 CNY m phx_cn_10jqka+phx_cn_est+fx_fed_h10 annual table, row 营业总收入
Pharmaceutical industry arm estimated as 12% of consolidate…Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)
2835.80亿 total x 12% = 34029.6 RMB m
Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C)
Shionogi2003 1707 – C 192,384 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 200,400 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Shionogi2004 1781 4.4 C 191,328 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 199,300 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Shionogi2005 1667 -6.4 C 188,448 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 196,300 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Shionogi2006 1639 -1.6 C 191,712 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 199,700 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Shionogi2007 1807 10.2 C 205,697 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 214,268 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Shionogi2008 2182 20.8 C 218,411 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 227,511 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Shionogi2009 2883 32.1 C 267,362 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 278,502 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Shionogi2010 3171 10.0 C 271,056 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 282,350 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Shionogi2011 3252 2.5 C 256,584 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.96
group net sales 267,275 x 0.96
Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Shire2000 500 – C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2001 600 20.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 600 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2002 800 33.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 800 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2003 1000 25.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2004 1300 30.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2005 1500 15.4 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2006 1700 13.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2007 1800 5.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2008 2000 11.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2000 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2009 2400 20.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2010 2700 12.5 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2700 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2011 3500 29.6 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2012 4700 34.3 C phx_ar_recall five/ten-year summary of the annual report (not located)
Total revenues (pure-play pharma; Shire Pharmaceuticals Gro…Total revenues (pure-play pharma; Shire Pharmaceuticals Group)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4700 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Shire2013 4847 3.1 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 4,847" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Shire2014 5830 20.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 5,830" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Shire2015 6100 4.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 6,100" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Shire2016 10886 78.5 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 10,886" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Shire2017 14449 32.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 14,449" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Shire2018 14993 3.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Shire ... 14,993" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Sichuan Kelun Pharmaceutical2007 267 – B 2,029 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 202,932.66" (10,000 CNY) = 2,029.33 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2008 377 41.4 B 2,621 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 262,139.13" (10,000 CNY) = 2,621.39 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2009 475 25.9 B 3,246 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 324,598.53" (10,000 CNY) = 3,245.99 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2010 595 25.2 B 4,026 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 402,640.00" (10,000 CNY) = 4,026.40 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2011 797 33.9 B 5,148 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 514,784.88" (10,000 CNY) = 5,147.85 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2012 933 17.1 B 5,885 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 588,527.86" (10,000 CNY) = 5,885.28 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2013 1111 19.1 B 6,831 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 683,128.20" (10,000 CNY) = 6,831.28 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2014 1302 17.2 B 8,023 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 802,342.13" (10,000 CNY) = 8,023.42 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2015 1236 -5.1 B 7,763 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 776,334.00" (10,000 CNY) = 7,763.34 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2016 1290 4.4 B 8,566 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 856,594.34" (10,000 CNY) = 8,565.94 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2017 1693 31.2 B 11,435 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入/营业收入 1,143,494.88" (10,000 CNY) = 11,434.95 m
Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader.
Sichuan Kelun Pharmaceutical2018 2477 46.3 B 16,352 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 163.52亿元" = 16352 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Sichuan Kelun Pharmaceutical2019 2554 3.1 B 17,636 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 176.36亿元" = 17636 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Sichuan Kelun Pharmaceutical2020 2388 -6.5 B 16,464 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 164.64亿元" = 16464 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Sichuan Kelun Pharmaceutical2021 2679 12.2 B 17,277 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 172.77亿元" = 17277 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Sichuan Kelun Pharmaceutical2022 2834 5.8 B 19,038 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 190.38亿元" = 19038 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Sichuan Kelun Pharmaceutical2023 3032 7.0 B 21,454 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 214.54亿元" = 21454 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Sichuan Kelun Pharmaceutical2024 3031 0.0 B 21,812 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 218.12亿元" = 21812 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Sichuan Kelun Pharmaceutical2025 2576 -15.0 B 18,513 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Sichuan Kelun Pharmaceu…Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)
"营业总收入 185.13亿元" = 18513 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Sino Biopharmaceutical2002 44 – B 343 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table
Continuing operations only (earlier businesses discontinued); HK$.
Sino Biopharmaceutical2003 59 33.3 B 456 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table
Continuing operations only (earlier businesses discontinued); HK$.
Sino Biopharmaceutical2004 85 45.6 B 664 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table
Continuing operations only (earlier businesses discontinued); HK$.
Sino Biopharmaceutical2005 97 14.0 B 756 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table
Continuing operations only (earlier businesses discontinued); HK$.
Sino Biopharmaceutical2006 95 -2.7 B 735 HKD m phx_cn_sino_ar06+fx_fed_h10 Five-year financial summary (read through a search snippet; column order inferred)
Turnover (pharmaceutical)Turnover (pharmaceutical)
2006 Annual Report five-year summary, continuing operations: 734,652 756,073 664,296 456,089 342,610 (HK$'000; order assumed 2006 to 2002, from the 2005 report chart showing 2003 = 456,089 and 2004 = 664,296)
Continuing operations only (earlier businesses discontinued); HK$.
Sino Biopharmaceutical2007 149 57.8 C 1,164 HKD m phx_sinobio_hkex+fx_fed_h10 2008 results announcement: 2008 turnover +96%
Turnover (pharmaceutical)Turnover (pharmaceutical)
2,282.21 / 1.96 = 1,164.4
Back-calculated from the stated growth of about 96% in 2008; no 2007 figure read directly.
Sino Biopharmaceutical2012 966 – B 7,497 HKD m phx_cn_sino_ar14+fx_fed_h10 Financial Summary (read via pdftotext)
Turnover (pharmaceutical)Turnover (pharmaceutical)
2014 AR Financial Summary: TURNOVER 12,378,350 9,901,196 7,496,888 5,171,354 3,618,773 (HK$'000, 2014 to 2010)
HK$ reporting currency. The same table restates 2010-2011 (3,618.8 and 5,171.4) below the earlier rows (4,086 and 5,782, as first reported) after a disposal; 2012 onward as reported.
Sino Biopharmaceutical2013 1277 32.1 B 9,901 HKD m phx_cn_sino_ar14+fx_fed_h10 Financial Summary (read via pdftotext)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table: 9,901,196
HK$ reporting currency. The same table restates 2010-2011 (3,618.8 and 5,171.4) below the earlier rows (4,086 and 5,782, as first reported) after a disposal; 2012 onward as reported.
Sino Biopharmaceutical2014 1596 25.1 B 12,378 HKD m phx_cn_sino_ar14+fx_fed_h10 Financial Summary (read via pdftotext)
Turnover (pharmaceutical)Turnover (pharmaceutical)
same table: 12,378,350
HK$ reporting currency. The same table restates 2010-2011 (3,618.8 and 5,171.4) below the earlier rows (4,086 and 5,782, as first reported) after a disposal; 2012 onward as reported.
Sino Biopharmaceutical2015 1877 17.6 B 14,550 HKD m phx_cn_sino_res15+fx_fed_h10 Management discussion, revenue paragraph
Turnover (pharmaceutical)Turnover (pharmaceutical)
The Group recorded revenue of approximately HK$14,550.23 million
HK$ reporting currency.
Sino Biopharmaceutical2016 2039 8.6 B 15,825 HKD m phx_cn_sino_res16+fx_fed_h10 Management discussion, revenue paragraph
Turnover (pharmaceutical)Turnover (pharmaceutical)
The Group recorded revenue of approximately HK$15,825.44 million
Last year in HK$; from FY2017 the group reports in RMB.
Sino Biopharmaceutical2017 2194 7.6 B 14,819 CNY m phx_cn_sino_res17+fx_fed_h10 Financial highlights (b)
Turnover (pharmaceutical)Turnover (pharmaceutical)
revenue of approximately RMB14,819.30 million, +9.4%
RMB from FY2017 (checked in the document); earlier rows are HK$.
Sino Biopharmaceutical2018 3142 43.2 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sino Biopharm ... 3,142" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Sino Biopharmaceutical2019 3373 7.4 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 42
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sino Biopharmaceutical ... 3,373" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Sino Biopharmaceutical2020 3430 1.7 B 23,647 CNY m phx_cn_sino_res+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
"Revenue RMB23,647.22 million, -2.4%"
RMB; continuing-operations basis as reported in each year
Sino Biopharmaceutical2021 4165 21.4 B 26,861 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
FY2021 26,861
RMB; continuing-operations basis as reported in each year
Sino Biopharmaceutical2022 3875 -7.0 B 26,026 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
FY2022 26,026
RMB; continuing-operations basis as reported in each year
Sino Biopharmaceutical2023 3703 -4.4 B 26,199 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
FY2023 26,199
RMB; continuing-operations basis as reported in each year
Sino Biopharmaceutical2024 4012 8.3 B 28,866 CNY m phx_cn_stockanalysis+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
FY2024 28,866
RMB; continuing-operations basis as reported in each year
Sino Biopharmaceutical2025 4429 10.4 B 31,834 CNY m phx_cn_sino_res+fx_fed_h10 results / financials table
Turnover (pharmaceutical)Turnover (pharmaceutical)
"Revenue 31.83 bn (2025) vs 28.87 bn (2024), +10.3%"
RMB; continuing-operations basis as reported in each year
STADA2000 554 – C 600 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 600 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2001 627 13.1 C 700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2002 756 20.6 C 800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2003 1019 34.7 C 900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2004 1244 22.1 C 1,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2005 1369 10.1 C 1,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2006 1633 19.3 C 1,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2007 1919 17.5 C 1,400 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1400 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2008 2206 14.9 C 1,500 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1500 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2009 2369 7.4 C 1,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2010 2522 6.5 C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2011 2645 4.9 C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2012 2701 2.1 C 2,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
STADA2013 2407 -10.9 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 46
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"STADA ... 2,407" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
STADA2014 2405 -0.1 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 45
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"STADA ... 2,405" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
STADA2017 2348 – B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 47
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"STADA ... 2,348" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
STADA2018 2467 5.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 49
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"STADA ... 2,467" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
STADA2020 2823 – B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
STADA2021 3097 9.7 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
STADA2023 3896 – B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
STADA2024 3930 0.9 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
STADA2025 4017 2.2 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Sumitomo Pharma2005 2000 – C 226,120 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 245,783 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Sumitomo Pharma2006 2055 2.8 C 240,316 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 261,213 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Sumitomo Pharma2007 2133 3.8 C 242,873 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 263,992 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Sumitomo Pharma2008 2427 13.8 C 242,914 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 264,037 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Sumitomo Pharma2009 2939 21.1 C 272,560 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 296,261 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Sumitomo Pharma2010 4085 39.0 C 349,152 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 379,513 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Sumitomo Pharma2011 4085 0.0 C 322,363 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical revenue estimate = consolidated net sales x …Pharmaceutical revenue estimate = consolidated net sales x 0.92
group net sales 350,395 x 0.92
Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Sumitomo Pharma2012 3286 -19.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 3,286" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Sumitomo Pharma2014 2944 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 2,944" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Sumitomo Pharma2015 2902 -1.4 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 2,902" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Sumitomo Pharma2016 3197 10.2 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 3,197" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Sumitomo Pharma2017 3528 10.4 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 3,528" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Sumitomo Pharma2018 3543 0.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 40
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon ... 3,543" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Sumitomo Pharma2019 3623 2.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 41
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sumitomo Dainippon Pharma ... 3,623" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Sumitomo Pharma2020 4028 11.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Sumitomo Pharma2021 4602 14.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Sun Pharma2001 157 – B 7,505 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 7,505 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2002 201 27.7 B 9,725 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 9,725 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2003 214 6.7 B 9,847 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 9,847 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2004 267 24.7 B 11,983 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 11,983 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2005 393 47.2 B 17,372 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 17,372 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2006 496 26.1 B 22,373 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 22,373 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2007 863 73.9 B 34,606 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 34,606 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2008 959 11.1 B 43,751 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 43,751 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2009 805 -16.1 B 38,086 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 38,086 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2010 1258 56.3 B 57,214 INR m phx_sun_ar+fx_fed_h10 Annual report 2010-11, ten-year highlights
Consolidated income from operations (pharma)Consolidated income from operations (pharma)
Income from Operations 57,214 (Rs m)
Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6).
Sun Pharma2012 2311 – B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 48
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 2,311" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Sun Pharma2014 5012 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 32
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 5,012" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Sun Pharma2015 4503 -10.2 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 31
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 4,503" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Sun Pharma2016 4804 6.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 4,804" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Sun Pharma2017 4147 -13.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 4,147" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Sun Pharma2018 4222 1.8 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma ... 4,222" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Sun Pharma2019 4658 10.3 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 33
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Sun Pharma Industries ... 4,658" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Sun Pharma2020 4630 -0.6 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Sun Pharma2021 5091 10.0 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Sun Pharma2022 5424 6.5 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Sun Pharma2023 5789 6.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Sun Pharma2024 6081 5.0 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Sun Pharma2025 6441 5.9 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Takeda2000 7504 – C 828,524 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 963,400 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2001 6919 -7.8 C 864,352 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,005,060 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2002 7387 6.8 C 899,630 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,046,081 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2003 8288 12.2 C 934,331 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,086,431 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2004 9035 9.0 B 970,500 JPY m phx_takeda_seg+fx_fed_h10 FY2005 (Mar 2005) results, segment split
Pharmaceutical business net sales (iyaku jigyo)Pharmaceutical business net sales (iyaku jigyo)
Pharmaceutical 970.5 bn yen (86%), other 152.5 bn (14%); total 1,122,960
Segment figure as quoted in a web-search result for the FY2005 results announcement; the announcement itself not opened. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2005 9220 2.1 C 1,042,498 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,212,207 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2006 9599 4.1 C 1,122,444 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,305,167 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2007 10385 8.2 C 1,182,330 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,374,802 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2008 13220 27.3 C 1,322,969 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,538,336 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2009 13592 2.8 C 1,260,730 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,465,965 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2010 14282 5.1 C 1,220,671 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,419,385 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2011 16445 15.1 C 1,297,682 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準), securities-report data
Pharmaceutical (Rx) revenue estimate = consolidated net sal…Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86
group net sales 1,508,932 x 0.86
Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Takeda2012 13591 -17.4 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 13,591" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Takeda2014 13038 – B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 17
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 13,038" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Takeda2015 12565 -3.6 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 18
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 12,565" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Takeda2016 12773 1.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 19
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 12,773" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Takeda2017 13577 6.3 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 20
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 13,577" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Takeda2018 17427 28.4 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 16
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 17,427" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Takeda2019 29747 70.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 10
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Takeda ... 29,747" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Takeda2020 27896 -6.2 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Takeda2021 29605 6.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Takeda2022 29690 0.3 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Takeda2023 27687 -6.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Takeda2024 29782 7.6 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Takeda2025 29671 -0.4 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Tasly Pharmaceutical2000 47 – B 392 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 39,158.28" (10,000 CNY) = 391.58 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2001 83 74.9 B 685 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 68,456.88" (10,000 CNY) = 684.57 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2002 112 35.8 B 930 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 92,979.17" (10,000 CNY) = 929.79 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2003 128 13.6 B 1,056 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 105,580.53" (10,000 CNY) = 1,055.81 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2004 157 23.3 B 1,302 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 130,177.76" (10,000 CNY) = 1,301.78 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2005 179 13.8 B 1,466 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 146,608.38" (10,000 CNY) = 1,466.08 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2006 303 69.5 B 2,417 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"主营业务收入 241,708.70" (10,000 CNY) = 2,417.09 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2007 368 21.2 B 2,795 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 279,490.58" (10,000 CNY) = 2,794.91 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2008 494 34.5 B 3,434 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 343,421.55" (10,000 CNY) = 3,434.22 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2009 585 18.2 B 3,993 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 399,264.53" (10,000 CNY) = 3,992.65 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2010 687 17.6 B 4,652 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 465,159.11" (10,000 CNY) = 4,651.59 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2011 1017 47.9 B 6,570 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 656,966.46" (10,000 CNY) = 6,569.66 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2012 1475 45.0 B 9,301 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 930,145.58" (10,000 CNY) = 9,301.46 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2013 1807 22.5 B 11,108 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,110,806.59" (10,000 CNY) = 11,108.07 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2014 2042 13.0 B 12,578 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,257,770.15" (10,000 CNY) = 12,577.70 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2015 2106 3.1 B 13,228 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,322,751.22" (10,000 CNY) = 13,227.51 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2016 2100 -0.2 B 13,946 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,394,549.70" (10,000 CNY) = 13,945.50 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2017 2383 13.4 B 16,094 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入/营业收入 1,609,415.00" (10,000 CNY) = 16,094.15 m
Sina Finance table for stock 600535. Pre-2007 line is main business revenue.
Tasly Pharmaceutical2018 2725 14.3 B 17,990 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 179.90亿元" = 17990 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Tasly Pharmaceutical2019 2752 1.0 B 18,998 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 189.98亿元" = 18998 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Tasly Pharmaceutical2020 1969 -28.4 B 13,576 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 135.76亿元" = 13576 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Tasly Pharmaceutical2021 1233 -37.4 B 7,952 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 79.52亿元" = 7952 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Tasly Pharmaceutical2022 1286 4.3 B 8,637 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 86.37亿元" = 8637 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Tasly Pharmaceutical2023 1226 -4.7 B 8,674 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 86.74亿元" = 8674 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Tasly Pharmaceutical2024 1181 -3.7 B 8,498 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 84.98亿元" = 8498 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Tasly Pharmaceutical2025 1146 -3.0 B 8,236 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (own drugs plus some co…Total revenue of the listed company (own drugs plus some commercial sales)
"营业总收入 82.36亿元" = 8236 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Teva2000 1200 – C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1200 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2001 1700 41.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2002 2500 47.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2500 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2003 3300 32.0 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2004 3900 18.2 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2005 5300 35.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2006 8400 58.5 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 8400 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2007 9400 11.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9400 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2008 11100 18.1 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11100 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2009 13900 25.2 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 13900 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2010 16100 15.8 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 16100 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2011 18300 13.7 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2012 20300 10.9 C phx_ar_recall five/ten-year summary of the annual report (not located)
Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 20300 USD m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
Teva2013 17563 -13.5 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 17,563" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
Teva2014 17474 -0.5 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 12
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 17,474" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
Teva2015 16982 -2.8 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 16,982" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
Teva2016 18462 8.7 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 13
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 18,462" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
Teva2017 18261 -1.1 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 14
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 18,261" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
Teva2018 13122 -28.1 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 21
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva ... 13,122" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Teva2019 11090 -15.5 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 22
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Teva Pharmaceutical Industries ... 11,090" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Teva2020 11009 -0.7 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Teva2021 10468 -4.9 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Teva2022 12071 15.3 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Teva2023 12500 3.6 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Teva2024 13495 8.0 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Teva2025 14077 4.3 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
UCB2000 1662 – C 1,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2001 1701 2.4 C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2002 1607 -5.5 C 1,700 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2003 2037 26.8 C 1,800 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2004 2363 16.0 C 1,900 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2005 2489 5.3 C 2,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2006 2889 16.0 C 2,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2007 4113 42.4 C 3,000 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3000 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2008 4852 18.0 C 3,300 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3300 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2009 4319 -11.0 C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2010 4116 -4.7 C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2011 4315 4.9 C 3,100 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2012 4116 -4.6 C 3,200 EUR m phx_ar_recall+fx_fed_h10 five/ten-year summary of the annual report (not located)
Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)
Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3200 EUR m
Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication.
UCB2013 3802 -7.6 B phx_pe2014 Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 35
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 3,802" (US$ m)
Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote
UCB2014 3715 -2.3 B phx_pe2015 Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 36
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 3,715" (US$ m)
Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote
UCB2015 3763 1.3 B phx_pe2016 Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 3,763" (US$ m)
Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote
UCB2016 4005 6.4 B phx_pe2017 Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 34
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 4,005" (US$ m)
Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote
UCB2017 4633 15.7 B phx_pe2018 Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 30
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 4,633" (US$ m)
Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote
UCB2018 5138 10.9 B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 5,138" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
UCB2019 5102 -0.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 29
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"UCB ... 5,102" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
UCB2020 5455 6.9 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
UCB2021 6395 17.2 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
UCB2022 5663 -11.4 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
UCB2023 5210 -8.0 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
UCB2024 6051 16.1 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
UCB2025 8244 36.2 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Vertex2018 3038 – B phx_pe2019 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 43
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Vertex ... 3,038" (US$ m)
Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions
Vertex2019 4161 37.0 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 39
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Vertex Pharmaceuticals ... 4,161" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Vertex2020 6203 49.1 B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Vertex2021 7573 22.1 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Vertex2022 8607 13.7 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Vertex2023 9869 14.7 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Vertex2024 11020 11.7 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Vertex2025 11971 8.6 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Viatris2020 11495 – B pharmexec_2021
Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)
The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion.
Viatris2021 17508 52.3 B pharmexec_2022
Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)
Total of the 50: US$855.9 billion.
Viatris2022 15999 -8.6 B pharmexec_2023
Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)
Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed.
Viatris2023 15228 -4.8 B pharmexec_2024
Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)
Total of the 50: US$868.2 billion.
Viatris2024 14534 -4.6 B pharmexec_2025
Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)
Total of the 50: US$934.2 billion.
Viatris2025 14090 -3.1 B pharmexec_2026
Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)
Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel.
Watson Pharmaceuticals2008 1770 – B phx_pe2010 Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
2000 / (1+13.1%)
2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough
Watson Pharmaceuticals2009 2000 13.0 B phx_pe2010 Pharm Exec 50 (May 2010), 2009 Rx sales table
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
watson 2.0 (US$ bn)
Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn
Watson Pharmaceuticals2011 3700 – B phx_pe2012 Pharm Exec 50 (June 2012), 2011 Rx sales company profiles
Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)
watson $3.7 bn
Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn
Wyeth2000 10200 – C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Healt…Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Wyeth2001 10900 6.9 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Healt…Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Wyeth2002 11400 4.6 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Healt…Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Wyeth2003 12600 10.5 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Healt…Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Wyeth2004 13900 10.3 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Healt…Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Wyeth2005 15000 7.9 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Healt…Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Wyeth2006 16300 8.7 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Healt…Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Wyeth2007 17900 9.8 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Healt…Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Wyeth2008 18300 2.2 C phx_est selected data / segment note
Total net revenue less Consumer Healthcare and Animal Healt…Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)
Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08)
Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K
Yamanouchi Pharmaceutical2001 3853 – B 481,300 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)
consolidated net sales 481,300
Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Yamanouchi Pharmaceutical2002 4160 8.0 B 506,600 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)
consolidated net sales 506,600
Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Yamanouchi Pharmaceutical2003 4535 9.0 B 511,200 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)
consolidated net sales 511,200
Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Yamanouchi Pharmaceutical2004 4162 -8.2 B 447,100 JPY m phx_shashi+fx_fed_h10 Table 売上高 (連結, 日本基準)
Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)
consolidated net sales 447,100
Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Yunnan Baiyao2000 96 – B 797 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 79,657.05" (10,000 CNY) = 796.57 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2001 109 13.2 B 901 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 90,144.02" (10,000 CNY) = 901.44 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2002 133 22.2 B 1,101 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 110,119.38" (10,000 CNY) = 1,101.19 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2003 163 22.3 B 1,346 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 134,634.63" (10,000 CNY) = 1,346.35 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2004 222 36.3 B 1,835 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 183,498.86" (10,000 CNY) = 1,834.99 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2005 299 34.9 B 2,451 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 245,083.98" (10,000 CNY) = 2,450.84 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2006 402 34.3 B 3,203 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"主营业务收入 320,273.74" (10,000 CNY) = 3,202.74 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2007 541 34.7 B 4,116 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 411,571.69" (10,000 CNY) = 4,115.72 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2008 824 52.2 B 5,723 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 572,319.87" (10,000 CNY) = 5,723.20 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2009 1050 27.4 B 7,172 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 717,178.40" (10,000 CNY) = 7,171.78 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2010 1489 41.8 B 10,075 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,007,543.78" (10,000 CNY) = 10,075.44 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2011 1751 17.6 B 11,312 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,131,232.24" (10,000 CNY) = 11,312.32 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2012 2170 23.9 B 13,687 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,368,682.45" (10,000 CNY) = 13,686.82 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2013 2573 18.6 B 15,815 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,581,479.09" (10,000 CNY) = 15,814.79 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2014 3054 18.7 B 18,814 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 1,881,436.64" (10,000 CNY) = 18,814.37 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2015 3301 8.1 B 20,738 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 2,073,812.62" (10,000 CNY) = 20,738.13 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2016 3376 2.3 B 22,411 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 2,241,065.44" (10,000 CNY) = 22,410.65 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2017 3600 6.7 B 24,315 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入/营业收入 2,431,461.40" (10,000 CNY) = 24,314.61 m
Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue.
Yunnan Baiyao2018 4092 13.7 B 27,017 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 270.17亿元" = 27017 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Yunnan Baiyao2019 4284 4.7 B phx_pe2020 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 37
Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)
"Yunnan Baiyao Group ... 4,284" (US$ m)
Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020
Yunnan Baiyao2020 4749 10.8 B 32,743 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 327.43亿元" = 32743 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Yunnan Baiyao2021 5640 18.8 B 36,374 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 363.74亿元" = 36374 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Yunnan Baiyao2022 5432 -3.7 B 36,488 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 364.88亿元" = 36488 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Yunnan Baiyao2023 5528 1.8 B 39,111 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 391.11亿元" = 39111 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Yunnan Baiyao2024 5564 0.6 B 40,033 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 400.33亿元" = 40033 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Yunnan Baiyao2025 5731 3.0 B 41,187 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue (own pharmaceutical/health products plus phar…Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)
"营业总收入 411.87亿元" = 41187 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Hisun Pharmaceutical2000 63 – B 518 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 51,823.65" (10,000 CNY) = 518.24 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2001 70 11.6 B 578 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 57,821.17" (10,000 CNY) = 578.21 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2002 92 32.0 B 763 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 76,308.32" (10,000 CNY) = 763.08 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2003 187 103.4 B 1,552 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 155,178.61" (10,000 CNY) = 1,551.79 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2004 215 14.8 B 1,781 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 178,075.12" (10,000 CNY) = 1,780.75 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2005 234 8.6 B 1,914 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 191,357.52" (10,000 CNY) = 1,913.58 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2006 286 22.5 B 2,280 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"主营业务收入 228,026.78" (10,000 CNY) = 2,280.27 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2007 373 30.5 B 2,839 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 283,877.07" (10,000 CNY) = 2,838.77 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2008 458 22.7 B 3,182 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 318,197.83" (10,000 CNY) = 3,181.98 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2009 586 27.9 B 4,003 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 400,347.04" (10,000 CNY) = 4,003.47 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2010 671 14.6 B 4,545 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 454,450.90" (10,000 CNY) = 4,544.51 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2011 799 19.0 B 5,161 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 516,139.42" (10,000 CNY) = 5,161.39 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2012 920 15.2 B 5,802 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 580,176.61" (10,000 CNY) = 5,801.77 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2013 1400 52.2 B 8,604 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 860,431.16" (10,000 CNY) = 8,604.31 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2014 1639 17.1 B 10,097 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 1,009,674.79" (10,000 CNY) = 10,096.75 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2015 1396 -14.9 B 8,767 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 876,742.81" (10,000 CNY) = 8,767.43 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2016 1466 5.0 B 9,733 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 973,342.35" (10,000 CNY) = 9,733.42 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2017 1565 6.8 B 10,572 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入/营业收入 1,057,152.67" (10,000 CNY) = 10,571.53 m
Sina Finance table for stock 600267.
Zhejiang Hisun Pharmaceutical2018 1543 -1.4 B 10,187 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 101.87亿元" = 10187 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Hisun Pharmaceutical2019 1604 3.9 B 11,072 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 110.72亿元" = 11072 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Hisun Pharmaceutical2020 1647 2.7 B 11,354 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 113.54亿元" = 11354 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Hisun Pharmaceutical2021 1794 9.0 B 11,572 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 115.72亿元" = 11572 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Hisun Pharmaceutical2022 1694 -5.6 B 11,379 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 113.79亿元" = 11379 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Hisun Pharmaceutical2023 1421 -16.1 B 10,053 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 100.53亿元" = 10053 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Hisun Pharmaceutical2024 1437 1.1 B 10,340 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 103.40亿元" = 10340 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Hisun Pharmaceutical2025 1468 2.2 B 10,550 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company Zhejiang Hisun Pharmace…Total revenue of the listed company Zhejiang Hisun Pharmaceutical
"营业总收入 105.50亿元" = 10550 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Medicine2000 133 – B 1,104 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 110,449.29" (10,000 CNY) = 1,104.49 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2001 105 -21.3 B 869 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 86,862.82" (10,000 CNY) = 868.63 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2002 135 28.6 B 1,117 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 111,701.21" (10,000 CNY) = 1,117.01 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2003 138 1.9 B 1,138 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 113,847.14" (10,000 CNY) = 1,138.47 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2004 168 21.8 B 1,387 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 138,682.97" (10,000 CNY) = 1,386.83 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2005 231 37.7 B 1,890 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 189,001.58" (10,000 CNY) = 1,890.02 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2006 276 19.6 B 2,199 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"主营业务收入 219,922.61" (10,000 CNY) = 2,199.23 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2007 290 5.3 B 2,209 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 220,882.56" (10,000 CNY) = 2,208.83 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2008 542 86.4 B 3,761 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 376,102.93" (10,000 CNY) = 3,761.03 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2009 612 13.1 B 4,184 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 418,374.08" (10,000 CNY) = 4,183.74 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2010 673 10.0 B 4,558 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 455,826.52" (10,000 CNY) = 4,558.27 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2011 747 10.9 B 4,826 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 482,596.84" (10,000 CNY) = 4,825.97 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2012 834 11.7 B 5,264 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 526,400.61" (10,000 CNY) = 5,264.01 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2013 802 -3.8 B 4,933 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 493,292.02" (10,000 CNY) = 4,932.92 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2014 784 -2.2 B 4,832 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 483,229.18" (10,000 CNY) = 4,832.29 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2015 716 -8.8 B 4,497 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 449,666.24" (10,000 CNY) = 4,496.66 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2016 795 11.1 B 5,279 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 527,920.40" (10,000 CNY) = 5,279.20 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2017 843 6.0 B 5,693 CNY m phx_cn_sina+fx_fed_h10 Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY)
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入/营业收入 569,258.04" (10,000 CNY) = 5,692.58 m
Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical.
Zhejiang Medicine2018 1039 23.3 B 6,859 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 68.59亿元" = 6859 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Medicine2019 1020 -1.8 B 7,044 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 70.44亿元" = 7044 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Medicine2020 1063 4.2 B 7,327 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 73.27亿元" = 7327 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Medicine2021 1415 33.2 B 9,129 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 91.29亿元" = 9129 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Medicine2022 1208 -14.6 B 8,116 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 81.16亿元" = 8116 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Medicine2023 1102 -8.8 B 7,794 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 77.94亿元" = 7794 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Medicine2024 1303 18.3 B 9,375 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 93.75亿元" = 9375 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
Zhejiang Medicine2025 1236 -5.2 B 8,881 CNY m phx_cn_10jqka+fx_fed_h10 annual table, row 营业总收入
Total revenue of the listed company (APIs, vitamins, formul…Total revenue of the listed company (APIs, vitamins, formulations)
"营业总收入 88.81亿元" = 8881 RMB m
Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table
ChugaiFY2001 – – uncertain 203000 JPY https://the-shashi.com/tse/4519/financi…
Fiscal year ended March until 2002, then December after the…Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). FY2000 and FY2001 are both 203,000 in the source: suspicious, so FY2001 is kept out of the chart. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named.
Sino Biopharmaceutical2008 – – uncertain 2282 HKD https://www1.hkexnews.hk/listedco/listc…
Currency (HKD vs RMB) taken from a search summary, not chec…Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain.
Sino Biopharmaceutical2009 – – uncertain 3244 HKD https://www1.hkexnews.hk/listedco/listc…
Currency (HKD vs RMB) taken from a search summary, not chec…Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain.
Sino Biopharmaceutical2010 – – uncertain 4086 HKD https://www1.hkexnews.hk/listedco/listc…
Currency (HKD vs RMB) taken from a search summary, not chec…Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain.
Sino Biopharmaceutical2011 – – uncertain 5782 HKD https://www1.hkexnews.hk/listedco/listc…
Currency (HKD vs RMB) taken from a search summary, not chec…Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain.
Yamanouchi PharmaceuticalFY1999/00 – – missing –
Yamanouchi sales for FY1999/00 and FY2000/01 not found in t…Yamanouchi sales for FY1999/00 and FY2000/01 not found in the sources reached.
Yamanouchi PharmaceuticalFY2000/01 – – missing –
Yamanouchi sales for FY1999/00 and FY2000/01 not found in t…Yamanouchi sales for FY1999/00 and FY2000/01 not found in the sources reached.
Fujisawa PharmaceuticalFY1999/00 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in the…Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
Fujisawa PharmaceuticalFY2000/01 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in the…Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
Fujisawa PharmaceuticalFY2001/02 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in the…Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
Fujisawa PharmaceuticalFY2002/03 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in the…Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
Fujisawa PharmaceuticalFY2003/04 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in the…Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
Fujisawa PharmaceuticalFY2004/05 – – missing –
Fujisawa Pharmaceutical consolidated sales not found in the…Fujisawa Pharmaceutical consolidated sales not found in the sources reached.
SankyoFY1999/00 – – missing –
Sankyo pharma sales not found except the FY2004/05 derivati…Sankyo pharma sales not found except the FY2004/05 derivation.
SankyoFY2000/01 – – missing –
Sankyo pharma sales not found except the FY2004/05 derivati…Sankyo pharma sales not found except the FY2004/05 derivation.
SankyoFY2001/02 – – missing –
Sankyo pharma sales not found except the FY2004/05 derivati…Sankyo pharma sales not found except the FY2004/05 derivation.
SankyoFY2002/03 – – missing –
Sankyo pharma sales not found except the FY2004/05 derivati…Sankyo pharma sales not found except the FY2004/05 derivation.
SankyoFY2003/04 – – missing –
Sankyo pharma sales not found except the FY2004/05 derivati…Sankyo pharma sales not found except the FY2004/05 derivation.
Daiichi PharmaceuticalFY1999/00 – – missing –
Selected Financial Data section of the 20-F not reached.Selected Financial Data section of the 20-F not reached.
Daiichi PharmaceuticalFY2000/01 – – missing –
Selected Financial Data section of the 20-F not reached.Selected Financial Data section of the 20-F not reached.
Daiichi PharmaceuticalFY2001/02 – – missing –
Selected Financial Data section of the 20-F not reached.Selected Financial Data section of the 20-F not reached.
ShionogiFY1999/00 – – missing –
Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,…Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used.
ShionogiFY2000/01 – – missing –
Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,…Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used.
ShionogiFY2001/02 – – missing –
Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,…Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used.
ShionogiFY2002/03 – – missing –
Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,…Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used.
OnoFY1999/00 – – missing –
Not found.Not found.
OnoFY2000/01 – – missing –
Not found.Not found.
OtsukaFY1999/00 – – missing –
Pre-2003 table is non-consolidated and not comparable.Pre-2003 table is non-consolidated and not comparable.
OtsukaFY2000/01 – – missing –
Pre-2003 table is non-consolidated and not comparable.Pre-2003 table is non-consolidated and not comparable.
OtsukaFY2001/02 – – missing –
Pre-2003 table is non-consolidated and not comparable.Pre-2003 table is non-consolidated and not comparable.
Mitsubishi PharmaFY1999/00 – – missing –
Mitsubishi Pharma sales not found in the sources reached (a…Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
Mitsubishi PharmaFY2000/01 – – missing –
Mitsubishi Pharma sales not found in the sources reached (a…Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
Mitsubishi PharmaFY2001/02 – – missing –
Mitsubishi Pharma sales not found in the sources reached (a…Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
Mitsubishi PharmaFY2002/03 – – missing –
Mitsubishi Pharma sales not found in the sources reached (a…Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
Mitsubishi PharmaFY2003/04 – – missing –
Mitsubishi Pharma sales not found in the sources reached (a…Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
Mitsubishi PharmaFY2004/05 – – missing –
Mitsubishi Pharma sales not found in the sources reached (a…Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
Mitsubishi PharmaFY2005/06 – – missing –
Mitsubishi Pharma sales not found in the sources reached (a…Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference).
Tanabe SeiyakuFY1999/00 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pres…Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
Tanabe SeiyakuFY2000/01 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pres…Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
Tanabe SeiyakuFY2001/02 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pres…Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
Tanabe SeiyakuFY2002/03 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pres…Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
Tanabe SeiyakuFY2003/04 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pres…Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
Tanabe SeiyakuFY2004/05 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pres…Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
Tanabe SeiyakuFY2005/06 – – missing –
Tanabe Seiyaku sales not found in the sources reached (pres…Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005).
Mitsubishi Tanabe PharmaFY2006/07 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
Mitsubishi Tanabe PharmaFY2007/08 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
Mitsubishi Tanabe PharmaFY2008/09 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
Mitsubishi Tanabe PharmaFY2009/10 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
Mitsubishi Tanabe PharmaFY2010/11 – – missing –
FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached.
Kyowa Kirin2000 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Kyowa Kirin2001 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Kyowa Kirin2002 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Kyowa Kirin2003 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Kyowa Kirin2004 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Kyowa Kirin2005 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Kyowa Kirin2006 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Kyowa Kirin2007 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Kyowa Kirin2008 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Kyowa Kirin2009 – – missing –
Kyowa Hakko pharma share of group sales (chemicals, bio, fo…Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found.
Dr. Reddy’sFY1999/00 – – missing –
Not found in the sources reached.Not found in the sources reached.
Dr. Reddy’sFY2000/01 – – missing –
Not found in the sources reached.Not found in the sources reached.
Dr. Reddy’sFY2001/02 – – missing –
Not found in the sources reached.Not found in the sources reached.
Dr. Reddy’sFY2002/03 – – missing –
Not found in the sources reached.Not found in the sources reached.
Dr. Reddy’sFY2003/04 – – missing –
Not found in the sources reached.Not found in the sources reached.
Dr. Reddy’sFY2004/05 – – missing –
Not found in the sources reached.Not found in the sources reached.
Dr. Reddy’sFY2005/06 – – missing –
Not found in the sources reached.Not found in the sources reached.
Dr. Reddy’sFY2006/07 – – missing –
Not found in the sources reached.Not found in the sources reached.
Ranbaxy2000 – – missing –
Consolidated sales not found (AR2010 ten-year table is stan…Consolidated sales not found (AR2010 ten-year table is standalone only).
Ranbaxy2001 – – missing –
Consolidated sales not found (AR2010 ten-year table is stan…Consolidated sales not found (AR2010 ten-year table is standalone only).
Ranbaxy2002 – – missing –
Consolidated sales not found (AR2010 ten-year table is stan…Consolidated sales not found (AR2010 ten-year table is standalone only).
Ranbaxy2003 – – missing –
Consolidated sales not found (AR2010 ten-year table is stan…Consolidated sales not found (AR2010 ten-year table is standalone only).
Ranbaxy2004 – – missing –
Consolidated sales not found (AR2010 ten-year table is stan…Consolidated sales not found (AR2010 ten-year table is standalone only).
Ranbaxy2005 – – missing –
Consolidated sales not found (AR2010 ten-year table is stan…Consolidated sales not found (AR2010 ten-year table is standalone only).
Ranbaxy2006 – – missing –
Consolidated sales not found (AR2010 ten-year table is stan…Consolidated sales not found (AR2010 ten-year table is standalone only).
Ranbaxy2007 – – missing –
Consolidated sales not found (AR2010 ten-year table is stan…Consolidated sales not found (AR2010 ten-year table is standalone only).
Sun PharmaFY1999/00 – – missing –
Not found (FY2012: 2012-13 annual report ten-year table not…Not found (FY2012: 2012-13 annual report ten-year table not reached).
Sun PharmaFY2000/01 – – missing –
Not found (FY2012: 2012-13 annual report ten-year table not…Not found (FY2012: 2012-13 annual report ten-year table not reached).
Sun PharmaFY2011/12 – – missing –
Not found (FY2012: 2012-13 annual report ten-year table not…Not found (FY2012: 2012-13 annual report ten-year table not reached).
Jiangsu Hengrui2000 – – missing –
Not found.Not found.
Jiangsu Hengrui2001 – – missing –
Not found.Not found.
Jiangsu Hengrui2002 – – missing –
Not found.Not found.
Jiangsu Hengrui2003 – – missing –
Not found.Not found.
Jiangsu Hengrui2004 – – missing –
Not found.Not found.
Jiangsu Hengrui2005 – – missing –
Not found.Not found.
Jiangsu Hengrui2006 – – missing –
Not found.Not found.
Jiangsu Hengrui2007 – – missing –
Not found.Not found.
Jiangsu Hengrui2008 – – missing –
Not found.Not found.
Jiangsu Hengrui2009 – – missing –
Not found.Not found.
Sino Biopharmaceutical2000 – – missing –
Not found.Not found.
Sino Biopharmaceutical2001 – – missing –
Not found.Not found.
Sino Biopharmaceutical2002 – – missing –
Not found.Not found.
Sino Biopharmaceutical2003 – – missing –
Not found.Not found.
Sino Biopharmaceutical2004 – – missing –
Not found.Not found.
Sino Biopharmaceutical2005 – – missing –
Not found.Not found.
Sino Biopharmaceutical2006 – – missing –
Not found.Not found.
Sino Biopharmaceutical2007 – – missing –
Not found.Not found.
Sino Biopharmaceutical2012 – – missing –
Not found.Not found.
CiplaFY1999/00 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2000/01 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2001/02 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2002/03 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2003/04 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2004/05 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2005/06 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2006/07 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2007/08 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2008/09 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2009/10 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2010/11 – – missing –
Not searched within the call budget.Not searched within the call budget.
CiplaFY2011/12 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY1999/00 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2000/01 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2001/02 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2002/03 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2003/04 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2004/05 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2005/06 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2006/07 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2007/08 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2008/09 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2009/10 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2010/11 – – missing –
Not searched within the call budget.Not searched within the call budget.
LupinFY2011/12 – – missing –
Not searched within the call budget.Not searched within the call budget.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2000 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2001 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2002 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2003 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2004 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2005 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2006 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2007 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2008 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2009 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2010 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2011 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2012 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2000 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2001 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2002 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2003 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2004 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2005 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2006 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2007 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2008 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2009 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2010 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2011 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Yunnan Baiyao2012 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2000 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2001 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2002 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2003 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2004 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2005 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2006 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2007 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2008 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2009 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2010 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2011 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CSPC Pharmaceutical2012 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2000 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2001 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2002 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2003 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2004 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2005 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2006 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2007 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2008 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2009 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2010 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2011 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Huadong Medicine2012 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2000 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2001 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2002 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2003 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2004 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2005 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2006 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2007 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2008 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2009 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2010 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2011 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Tasly Pharmaceutical2012 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2000 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2001 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2002 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2003 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2004 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2005 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2006 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2007 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2008 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2009 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2010 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2011 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Harbin Pharmaceutical Group2012 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2000 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2001 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2002 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2003 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2004 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2005 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2006 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2007 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2008 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2009 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2010 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2011 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
North China Pharmaceutical2012 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2000 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2001 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2002 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2003 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2004 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2005 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2006 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2007 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2008 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2009 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2010 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2011 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
CJ CheilJedang2012 – – missing –
Not searched within the call budget; Chinese and Korean pha…Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open.
Biogen2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Biogen2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Biogen2002 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Biogen2003 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Biogen2004 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Biogen2005 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Biogen2006 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Biogen2007 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Biogen2010 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Biogen2012 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genzyme2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genzyme2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genzyme2002 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genzyme2003 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genzyme2004 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genzyme2005 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genzyme2006 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genzyme2007 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2002 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2003 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2004 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2005 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2006 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2007 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2010 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Forest Laboratories2012 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2002 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2003 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2004 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2005 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2006 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2007 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2008 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2009 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
King Pharmaceuticals2010 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2002 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2003 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2004 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2005 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2006 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2007 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2010 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Watson Pharmaceuticals2012 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Mylan2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Mylan2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Mylan2002 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Mylan2003 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Mylan2004 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Mylan2005 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Mylan2006 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Mylan2007 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2002 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2003 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2004 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2005 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2006 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2007 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2010 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Baxter2012 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Allergan2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Allergan2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Gilead Sciences2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Gilead Sciences2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Gilead Sciences2003 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Celgene2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Celgene2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Celgene2002 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genentech2000 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genentech2001 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genentech2002 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Genentech2003 – – missing –
No pharma-basis figure found within the research budget; fi…No pharma-basis figure found within the research budget; fill from the 10-K ten-year table
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2013 – – missing https://www1.hkexnews.hk/listedco/listc…
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, …Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2014 – – missing https://www1.hkexnews.hk/listedco/listc…
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, …Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2015 – – missing https://www1.hkexnews.hk/listedco/listc…
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, …Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2016 – – missing https://www1.hkexnews.hk/listedco/listc…
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, …Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.
Sinopharm (China National Pharmaceutical Group / Sinopharm Group)2017 – – missing https://www1.hkexnews.hk/listedco/listc…
Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, …Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found.

Data audit

Every revenue figure behind the tool, with the document it was read from. Grade A is a company's reported revenue for the business; B is derived from reported figures or taken from a tracker; C is a modelled estimate. Rows marked uncertain, missing or below_100m (under US$100 million a year, the inclusion line) are not in the chart.